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3 B TRACT 
Backgro und- Type _ d iabete me l l i tus preva lence i increas ing dramatical l )  un iversal ly and 
I a l l ) . Diabet ic  pat ient have ho\\ n h igher risk of i nfect ions and associated morb id i ty . 
1an) 1:1ctor cou ld  contr i bute to th is ,  inc l ud ing poor nutr it ional status of  th i s  popu lat ion.  The 
la k of evidence in th i s  fi e ld  i nsp i red us to look at the re lat ion h i p  between the d ietary 
upplement and ri k of i n fection in the e pat ient s .  
Objecth c- to  measure  the effect of d ietary supplement on r i sk  of i n fection i n  communi ty 
based pat ients \\ i tb type 2 d iabete me l l  i tus .  
Methods- fol l o\\ i ng  i n formed \uitten consent 1 00 d iabet ic  pat ients have been randomly 
as igned to receive e i ther an ora l  do e of  da i ly B-group itam ins  ( 1 .67  mg fo l ic ac id,  1 . 67mg 
\ itamin  B-2, 20 .86 mg itam in  8 -6, 0. 1 34 mg itam in B- 1 2 ) and antiox idant v i tam ins  
(22 1 mg) of  a-tocopherol and 1 67mg of v i tam in  C )  [ n=50 ] ,  or an ident ical  p lacebo [n= 50 ]  
dai l y  for 90 days. A l l  subjects had three assessments, at base l i ne, 3 ,  and  1 2  months post­
random izat ion .  The a sessment i nc l uded c l i n ica l  vari ables and se l f-repOt t i ng  i nfect ions .  I t  
a l  0 i nc luded i n format ion  relevant to i n fect ions such as phys ica l  act i v i ty and food i ntake. A 
fa t i ng  I O-ml  of  b lood v. as a l so col lected for measurements of serum v i tam in leve l s  and 
other re lated b iochemica l  variables .  
Re ult  - We found that.  the t reatment group who recei ved the V itam in  supp lements shovved 
s ign i ficant i mprovement in the b lood v i tam ins  concentrat ion compared with the p lacebo 
group ( V itam i n  E: p =0.005 , V itam in  A; p =0.002, fo late; p =0.00 1 ) . We a l so found that the 
number of i n fections  \\ ere lower i n  treatment group compared \ ith p lacebo group at three 
month ho\\ e er the d i fference \Va not stat i st ica l l y  s ign i ficant. Th i s  d i fference \Vas st i l l  
pre ent at 1 2  months but was less than that at 3 months .  
Con c l usion- the study showed that mu l t iv itam ins  supplements improved v i tam in b lood 
concentrat ions and non-s ign i ficant ly reduced the number of i n fect ions in d iabet ic  pat ients. 
Larger im i lar stud ies are needed to determ ine the requ i red dai ly  dose of v i tam ins  and 
durat ion of supplements in d iabet ic  and non-d iabet ic  pat ients at h i gher risk of  i nfect ions. 
KEY WORDS: d ietary supplement, r isk of  i n fect ion ,  type 2 d iabetes mel l i t ll s ,  B -group 
v i tam ins, and ant ioxidant v i tam ins  
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INTRODUCTION 
C h a p t e r  I 
8 I T RO DUCT I ON 
8. 1 Dia bete defin i t ion  a n d  prev a lence w o rldw ide 
Diabete 1 e l l i tus (D 1) i defi ned as a group of metabo l ic d i  ea es that assoc iated \\ ith 
i ncreased b lood g luco e l eve l ;  i t  i s  a condit ion where the body is not capab le to regu late 
bl od g luco e level s .  \\ h i ch  lead to i nc rease i n  the Ie el of gl ucose i n  the b lood, main ly  
re lated to  a combinat ion of  hered i tary and  env i ronmental causes, over t ime .  H igh b lood 
g l uco e level rna harm b lood esse l s  and nerves . These compl icat ions of d iabetes can 
cause i njur) to eye . nerve and k idneys and increase the risk of heart attacks. strokes. 
impotence and foot problems.  Th i  damage can bappen before an i nd iv idua l  knows if they 
ha\ e d iabetes or i f  d iabetes is unnoti ced for a long t ime.  ( World Health Organizat ion 
Department of  oncommun icable Disease urvei l Iance ( 1 999) ( I ) . 
There are two main  types of DM : " type I diabetes" \\ h ich i nc l udes ch i ldhood-on et d iabetes. 
jU\ en i l e  d iabetes. and i n su l in -dependent d iabetes mel l i tus (lO D M ). and " type 2 d iabetes" 
\\ h ich  i nc l udes adu lt-onset d iabetes, obes ity-re lated d iabetes. and non-i nsu l i n-dependent 
d iabetes mel l i tu (N I DD M) .  I n  add it ion there are some other types such as ge tat ional 
d iabetes (l ) .  
Type 1 D M  i s  an auto immune d i sease characterized by destruct ion of the  i nsu l i n­
produc ing beta ce l l s  i n  the pancreas resu l t i ng i n  a deficiency of i n su l i n .  Most of  type I 
d i abetes i s  of  the immune-med iated variety, where beta ce l l  l oss i s  as a resu l t  of T-ce i l  
med iated auto immune attack .  There i s  n o  known prevent ive measure wh ich can b e  taken 
aga inst t) pe 1 DM.  and it forms about 1 0% of d iabetes mel l i tus cases in North America and 
Europe (2 ) . 
Type 2 D M  i s  a d i sorder that i s  characterized by h igh b lood g lucose and assoc iated 
\\ ith i nsu l i n  res i stance wi th  re lat i ve i nsu l i n defic iency. W h i le it is often i n iti a l l y  managed by 
pr mot ing phy ical  acti i t i e  and d ietar )  mod i ficat ion,  med icat ion are usua l l )  needed as the 
d i sca  e progr e  se . bout 90°'0 of the d i agno ed OM pat ient in ar e t) pe 2 ( 3 ) . 
D iabetes me l l i tus (OM) repre  ents a major pub l i c  health problem un i  er sal ly; in  
2000, accord ing  to th v or ld  Health Or ganizat ion ,  at least 1 7 1  m i l l ion people \\ or ld\\ ide 
u ffer from d iabete , or 2 . 8°'0 of  the popu lat ion .  I t s  occurrence i s  increa ing qu ickly,  and it i 
expected that b) the year 20"'0,  th i  number w i l l  approxi mate ly  double .  Diabetes mel l itus 
occurs a l l  0\ er the \\ or ld .  but i more  frequent (espec ia l l y  type 2 )  i n  the more developed 
ountr ies .  The gr eatest i ncrea e in pre a lence is ,  however ,  expected to occur in Asia and 
fr ica.  Th i ncr ease i n  occurr ence of d iabete in deve lop ing countr ies fo l l o\ s the 
de\ lopment of a " We tern-sty le" l i fe sty le i nc lud ing h igh calor ic d iet and lack of physical 
act iv ity (4 ) .  
8 .2  Diabete i n  t h e  UAE 
n i ted Arab E m irates ( U A E )  is a federat ion of seven emirates s i tuated in the southeast of the 
rabian Pen i nsu la  in South\ est As ia  on the Ar abian Gu l f, bor der ing Oman and audi 
Arabia .  The U E cons ists of  se en states, cal led emirates, wh ich ar e Abu Dhab i .  Duba i ,  
harjah, Ajman, Umm a l -Quwa in ,  Ras  a l -Khai mah and Fujair ah .  The capital  and econd 
lar gest c it) of the n i ted Arab E m irates is Abu Dhab i .  Estab l i shed fir st as a nat ion in 1 97 1  
( 5 ) ,  the A E  has developed and grown rap id ly  s ince the 1 97 1 ,  and the commun ity gradua l l y  
moved from the  pro far mer l i fe sty le  depend ing on an i mal husbandry  and  date product ion to 
the modern sty le  soc iety depend ing  on producing o i l  and o i l  based products. These qu ick 
mod ificat ions have many impacts on the UAE soc iety uch as improved educat ion and 
gr o\\'i ng weal th ,  \v h i ch  lead to decr eas ing the leve l s  of phys ica l  act iv i t ies and increas ing 
consumpt ion of  fast food which is r ich  i n  ca lor ies, that lead to i ncrease rate of obesity and 
other re lated health problems such as type 2 OM. 
In the UAE d iabetes i s  one of the most common d i seases in the country .  As the case 
in other Arab countr ies, ther e  are ver y  few stud ies on prevalence of d iabetes in the UAE.  A 
recent study carr ied out i n  Abu Dhabi and sponsored by the WHO showed that a lmost 26% 
of UAE nat iona ls  suffer from the d i sease, th i s  per centage increased to 40% among those 
aged 60 and above. (9 ) .  
2 
Dr Prem Jag)- a  L healthcare management con u l tant said at the launch of the d iabetes 
a\\ ar nc campaign in Dubai  i n  2001" U E at pre ent ha the second h ighest rate of 
d iabetc \\ orld\\ ide··. J agya i ha  pub l i  hed a report ent i t led Un ite for D iabetes 2007. which 
conta in  research on 7000 i nd iv iduals from 1 00 d i fferent nationa l i t ies i n  the  UAE.  The 
re earch found that a lmo t 75% of nat ional s \v ere 0 erweight or obese. The paper a lso 
h \\ ed that the average yearl y  co t of  treatment i n  2007 \vas $993 per d iabet ic pat ient. whi le  
the LAE' xpense on d iabete -related treatment is expected to i ncrease to $ 1  bi l l ion by 
202 - . The E spent 436  m i l l ion ( 1 .6 bi l l ion d i rham) on d iabetes-re lated treatments i n  
2007 ( 1 9) .  Genet i c  factor ha\ e a v i ta l  ro le i n  d iabetes. bu t  env ironmental factors can' t be 
ignored a the) have s ign i ficant parts, that contribute to the d i sease development and 
prognosis .  The i nteract ions bet\\ een these two groups of factors make the abi l ity to prevent 
or dela) the compl icat ions of the di ease poss ib le  ( 1 3 7) .  
8.3 T h e  I m m u ne sy tem and risk of i n fection 
The immune system pro ides defense barriers agai nst any m ic robia l  i nvas ion; this system 
inc l udes the i nnate and acqu i red immun i ty. The i nnate immune system is the fi rst defense 
l i ne aga inst an) fore ign organ i sm.  [ nnate immun i ty pro ides an immed iate, but non-spec i fic  
re pon e. does not  need pre ious exposure .  Some of the barriers i n  th i s  system inc l ude: 
tructural barriers wh ich  prevent pathogens entry such as the sk in and mucou membranes; 
the ski n for examp le  can lessen most of bacteria l  grO\vth because of the low P H .  On the other 
hand some prote ins  in the sa l iva and mucus have the ab i l ity to destroy some pathogens .  Other 
type of the innate immun ity i nvo lves phys io logical  defenses such as temperature, PH ,  and 
oxygen leve l s .  The low P H  of the stomach for example p lays a ro le  in prevent ing infection 
(20) .  
The adaptive immun ity is act ivated by the i nnate response throughout an i n fection to 
improve its detect ion of the pathogen .  Composed of h igh ly  spec ia l ized systemic ce l l s ,  and 
processes, those remo e or prevent pathogenic threats .  So it  starts to work as a resu l t  of 
prev ious contact and memory; the adapt ive immune response is ant igen-spec i fic and need 
the detect ion of spec ific  " non-self' ant igens throughout a process ca l led ant igen presentat ion . 
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Antigen pec i fic i t)  I ad to pr duct ion of responses that are adapted to spec ific pathogens or 
pathogen- infected e l l  ( 1 5 ) . 
8A I m m u n ity a nd ri k of i n fection i n  d iabetic patient 
ome � ature of immun ity are affect d i n  d iabet ic pat ients. D iabet ic pat ients showed 
al terat ion i n  a l l  step of pol )  morphonuc lear neutroph i l  performance (28 ).The funct ion of 
Po l)  l110 rphOnll c lear leukocyte is reduced, mai n l  i f  a soc iated w i th acidos i s .  Leukocyte 
adherence, chemo taxi , and phagocytosi ma be i nfluenced (29, 30,  3 1 ) . A I  0 Impa i rment 
of ant io;\. idant coord inat ion which ha a ro le  in bacteric idal act iv ity has been noted (27) .  
I t  i s  genera l l y  accepted that the mortal i ty  rates of the type 2 d i abet ic  pat ient are more 
than non-d iabet ic  pat i ents .  Many factors can contribute to that, but the macrovascu lar and 
microva cu lar comp l i cat ions are genera l l y  the main causes. A prospect ive study with 47 1 
Braz i l ian t) pe '- d iabet ic  outpat ients showed that i n fect ion-re lated morta l it) among type 2 
d iabet ic  pat ient are ix-fo lds  more than general popu lat ion, the i ncreas ing i n  morta l it y  
ma in l y  determ i ned by  macrovascu lar and m icrovascu lar compl ications ( 5 5 ) . 
A n  a oc iat ion beh v een d iabetes and bacterial i nfect ion has been recogn ized for many year 
(6. 1 1 3 ) .  In an i ma l  and i n  v i tro stud ies. the host ' s  immune funct ions were repolied to be 
di turbed b) sholi - or long-term hyperg lycemia. i nc l ud i ng  neutroph i l  bacteric ida l  function, 
( 7) cel l u lar i mm ll n i t  , ( 8 )  and complement act ivat ion (9). These defects in the immune 
system, a long with va cu l ar i nsuffic iency. render d iabet ic  pat i ents at h igher r isk for a variety 
of severe or i nvas ive i n fect ions, such as pyogen ic bacter ia l  i n fect ions, necrot iz ing i nfect ions, 
Cand ida i n fect ions.  or other fung i  i n fections (4) .  
D iabetes M e l l i t u  showed contribution to an i ncreased r isk o f T B  ( 1 \ ) . In another 
stud) it has been found t hat no c lear re l at ionsh i p  of Mycobacterium avium subspec ies 
paratubercu los i s  \\' i th the i nc idence of Type 2 DM in ard i n ian pat ients ( 1 2 ) .  The risk of Post 
Operat ive I n fection and length  of stay in the hospital was increased by postoperat i e 
hy pergl y cemia  ( 1 4 ) .  
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enera l l_ it i accepted that d iabetes increa es the r isk of morbid i ty and mortal ity 
( 27). and \\ ound i n fect ions and no ocomia l  che t infect ions are more frequent i n  d iabetes 
(:2 - . 26) .  orne tudie sugge ted increa ed ri k of bacteria l  i n fect ion in d i abet ic pat ients (22) .  
Pro pect ive analy i s  of  i n fcct i  e endocard i t i s  ( I E) pat ients older than 1 5  years. \Vas 
ndu ted dur ing a 1 6-month-pc riod i n  ix French regions sho\\ ed  that I n su l in-OM. hm e a 
trong pred ict i v e rate i n  pat ients \" ith I E  (23) . l t  \ a uggested that the risk of i nfection in 
d iabet i pat i ent can be reduced by good contro l  of blood gl ucose. even though some c l i n ical 
data doe n't support thi ugge t ion (24) .  
8.5 Dia bete . Nutri t ion a n d  I m m u n i ty :  
The re lat ion h i p  bet\\ een n utr i t ion and i nfect ion i s  one of the fie lds that have been stud ied by 
man) researches in the last 40 years. It was in 1 968 when the WHO pub l i shed the fi rst 
i\10nograph or " I nteract ions between nutr it ion and i n fection" \ h i ch  reported that many 
i nfect ions " ere increased i n  pre a lence and severity by spec i fic nutr i t ional deficienC) . 
l ncrea ed uscept i b i l i ty to i n fection of malnouri shed ind iv idua ls  has a l so been demonstrated. 
o the re lat ion h i p  bet\\een ma lnutr i t ion and i nfect ion i s  I ike ly  to be synergist ic  ( 1 6 ). Some 
studies targeted the re l at ionsh i p  between nutrients and ind iv idual defenses against i nfection, 
and a l so the effect of  i n fection on the nutr i t ional status .  
1a l nutr i t ion has an assoc iat ion " ith immunodefic iency. worldwide.  The c l i n ical 
pathway and end resu l t s  of  some i n fections such as bacteria l  and v i ra l  d iarrhea. meas les. and 
tubercu los is  were ad erse l y  affected by nutr i t ional deficienc . W h i le in others the effect of 
nutr i t ional status is m i n imal . It is no\\ wel l -kno\vn that nutr i t iona l  defic iency is frequent ly  
assoc iated wi th  impa i red immune responses, most ly cel l -mediated immun i ty .  phagocyte 
funct ion.  cytokine product ion, ant ibody response, ant ibody affi n ity, and the comp lement 
ystem (6. 1 1 3 ) .  
Recent stud ies have demonstrated the ro le of spec ific  nutrients on the immun i ty 
process (20) .  Recent ly  the ro le  of m icronutrients on i n fect ion, immun ity, and in flammation 
has extended to i n c l ude not on ly  the prote in -energy supply ,  but a l so severa l v i tam ins, and 
m inera l s .  In experimental an ima ls, V i tam i n  A-defi c iency reduced the thymus and spleen s ize, 
reduced the act i  i ty of natura l  k i l ler cel l ,  reduced the production of i nterferon. decrea ed 
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efft c ienc) of fat macrophage act iv i t , and reduced the re ponse of Iymphoc) te re ponse to 
t imu lation b) m i togen ( 1 7 ) .  ome stud ie ha e hown that mal nutrit ion impa i rs elements of 
adapti \ e  and i nnate immun it) ( 1 8 ) .  
I t  i genera l l} accepted that that both Type I and Type I I  d iabetes me l l itus can cause 
ome changes i n  certa i n  m icronutrient (32 ) .  83% of hospital consu l tant epi odes for 
malnutr i t ion-re lated d i abete mel l i tu requ i red hospital admiss ion i n  England 2002-03 , 
resu l ted i n  increase length of tay for these pat ients for up to 5 . 6  day on average ( 3 3 ). 
8.6 D ietary u p ple m e n t  
I n  the  Oietar) upplement Health and  Education Act (0 HEA)  of 1 994 a d ietary upplement 
is defined a "a product taken b mouth that conta ins  a "d ietar) i ngred ient" intended to 
supplement the d iet . The "d ietary ingred ients" in these products ma i nc l ude:  v i tam ins ,  
m ineral . herb or other botan ica ls .  amino ac ids,  and substances such as enzymes, organ 
ti ue , g landu lar, and metabo l ites. D ietar supplements can a lso be extracts or concentrates, 
and ma) be found in man forms uch as tablets, capsu les, soft ge ls ,  ge l caps, l iqu ids,  or 
pO\\ ders .  The, can a l so be i n  other forms, such as a bar, but i f  they are, i n format ion on the ir 
labe l  must not represent  the product as a convent ional food or a sole item of a meal or d iet. 
\\l atever the ir  form may be, OSHEA p laces d ietary supp lements in a spec ia l  category under 
the genera l umbre l la  of " foods," not drugs, and requ i res that every upplement be l abe led a 
d ietar) supplement" ( 34 ) .  
The  Dietary Supp lement Health and  Education Act  ( OSH EA) of 1 994 defi ned 
v i tam ins  and m i nerals under the terms "d ietary ingred ient" as components of d ietary 
supp lements. These components seem to p lay a ro le  in improving the health status .  
Researches documented the benefi t  of d ietary supplements in health promotion and d i sease 
prevention ( 3 5 .  36,  1 36) .  
Accord i ng to ( O S H EA)  about 50% of Americans consume d ietary supplements of 
v i tam ins ,  m inera l s, and herbs regu lar ly as part of improving the i r  nutr it ion (34) .  General 
pract ice of us ing itam ins  is to correct v i tam in  defic iency, a l though cer1a in  v itam ins showed 
l i n k  to some d i sease prevent ion such as cancer ( 3 8 ), heart d i sease ( 39) ,  and osteoporos is  (40), 
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but u ing them a pal1 of  the pre ent i  e trateg) t i l l  requ i re further re earches. because the 
e\. idence for the ir  b nefi t  i i ncomplete. 
D ietar) upp lement are mai n l  recommended to the people who don ' t  consume 
u ffic ient food . Ph), ic ian genera l l )  ad i se certai n groups of people to use these 
upplement . uch a young ch i l dren who don ' t  take so l i d  foods, and elderly people with low 
food i ntake. Pregnant \\ omen are recommended b) the U . .  Prevent i ve erv ices Task Force 
to use da i l ) mu l t i  itam i n  \ i th m ineral supplement to reduce the r isk of b i rth  defects ( 1 1 4 ) .  
H igher consumpt ion of  d ietar supplements ( ma in ly  mu lt i nutrient supp lement) were main ly  
assoc iated \ i th certa in  groups of  people such as  female, with h igher educat ion.  h igher 
i ncome, \\ h i te peop le, and old age ( 1 1 5 , 1 1 6 , 1 1 7 ) .  
V i tam ins  and m inerals form a major part of  the i ngred ients of  the d ietary upplements 
u ed by health) people as prevent ive measures agai nst some d i seases such as i n fect ions. 
V i tam in  C \\ a the most common e lement l i sted i n  the products register of the th i rd Nat ional 
Health and utl' i t ion Exam inat ion Surve (NHANE I I I ) . The report l i sted some of the other 
main ingred ients used in the d ietary supplements in the U . S .A inc lud i ng;  fo l ic ac ids, v i tam in 
B 1 2 , B6. B2 .  A, E ,  and 0 ( 59 ) .  
8 . 7  V i ta m i n  C 
Vitamin  C i s  essent ia l  for the growth and repair  of t i ssues. I t  i s  req u i red to form co l lagen , 
\\ h ich i s  the protein used to bu i l d  ski n .  and many other t i ssues. V i tam in  C i impol1ant for 
wound hea l i ng, and for the repa i r  and maintenance of bones, teeth ,  and cart i l age. I t  a lso 
ass i st s  i n  the synthes i s  of  neurotransm itters (45 ). and metabo l i sm of cholestero l (46) .  
V i tam in  C may p lay a rol e  in he lp i ng the immune system defend ing the foreign 
bod ies and checki ng the systems for any s igns of cancer ce l l s .  It a l so contri butes i n  
moti at ing the manufactur ing of wh ite b lood cel l s  ma in ly  neutroph i l s, wh ich  react to  forei gn 
bod ies attack, l ike v i ruses and bacteria. I t  a l so enhances the body's creat ion of ant ibod ies and 
i nterferon, wh ich assi st in protect ion from v i ra l  attacks and tumor ce l l s  (42) .  V i tam in  C as 
anti oxidant, funct ions by st imu lat ing the immune system and defend ing  again  t harm from 
the free rad icals re leased by the body during the process of the body fight i ng aga inst the 
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i nfection (43 ). I t  he lp  i n  increa ing interferon Ie e l  of the  body , and eems to  decrea e the 
everit) and length of i l l nes e (44).  I t  has been reported that i ntravenou admin i strat ion of I 
gram 0 f v i tam in  to hea I th)  people,  igni  ficant l) increased the mot i )  i ly 0 f the neutroph i I s  
and tran!:.formation of  leukocyte (45) .  
I t  \\ a reported that the level of vi tam in  C i n  the p lasma and wh ite b lood cel l s  of 
d iabet ic  pat ient are I \ \  (4 1 ) . P ia  ma Ie e l s  of i tam in  were found to be s ign i ficant l)  h igher 
in nond iabet ic  contro l  ubjects compared \\ i th d iabet ic  subjects in many stud ies 
(4 1 , 1 1 8 , I ( 9) ,  therefore d iabet ic pat ient cou ld be more vu lnerab le  to oxidati e stres ( 1 1 8 ) .  
\\ h ich i s  ugge ted to contribute i n  the de e lopment of chron ic d iabetes compl ications ( 1 20) .  
o there has been benefit of us i ng d ietar ant iox idants to help i n  management of d iabet ic 
nephropathy . C l  i n ica l  stud ies proposed that the use of ant ioxidants may hel ps in the 
pre\'ention or rect i  ficat ion of d iabet ic nephropathy ( 1 2 1 , 1 22 ) .  
8 . 8  V i tam i n  E 
V itamin  E is a fat- o l ub le  and ant ioxidant v i tam in  protects body t i ssue from damage caused 
b) free rad ica ls .  V i tam i n  E is bel ieved to be involved in certa i n  cond i t ions assoc iated with 
aging (47) ,  In a p lacebo-contro l led, double-b l i nd trial i n  e lder ly ind iv iduals ,  v i tam in E 
upplementat ion enhanced immune response, part i cu lar ly delayed-type hypersens i t iv ity and 
re ponse to vacc ines (48 ) .  
I n  a randomized contro l l ed tr ia l ,  i nd iv idua ls  recei ved v i tam in  E for 6-month showed a 
30% lower i nc idence of i n fect ious d iseases, compared with tho e who rece ived the placebo, 
but the resu l t  was not stat i st ica l ly  s ign i ficant. Vi tam in  E supplements may decrease upper 
respi ratory tract i n fect ions,  most ly common colds .  with no effect on lower respi ratory tract 
i n fect ions or seasona l  i n fect ions ( 50) .  
The i nc idence of  vascu lar d i seases in d iabet ic patients i ncreased compared with non­
diabet ic pat ients (49) .  H igh b lood sligar i n  d iabet ic  pat ients may promote perox idation of 
l i p id  1 23 ), which i nvo l ved i n  the deve lopment of d iabet ic  compl icat ions such as chronic 
vascu lar d i sease (1 24) .  Many stud ies have invest igated the impact of some m icronutrients 
d ietar i ntake on p lasma l i p id  concentrat ions .  Some studies have stated that d ietary Vitam ins 
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� and upplementat ion are u fu l i n  improv ing plasma l i p id  Ie e l s  ( 1 25 , 1 26. 1 27 ) . But the 
effect of  the e \ itam in  remain  unc lear \\ i th ome other tudie showing no changes 
( 1 28 . 1 29) .  
8.9  B gl'O U p  v i ta m i n  
The B G roup itam in  are water- o lub le  ubstance , cons i st o f  i tam ins  that are qu ite 
d i  fferent i n  the ir  chem ica l  structure but are grouped together because the) were fi rst i o lated 
a a v i tam in  complex from yea t and l iver. ome of Vitam in  B group part icu larly v i tamin  B-
6, \ i tam in  B- 1 2  and fo late p lay ital ro les i n  synthesi of  prote in and nucleic ac id (54) .  
hortage of  these m ic ron utrients can  cause remarkab le decrease i n  body res i stance to 
i n fect ion and lymphocyte function that are important for the body to produce energy from 
fat . prote in .  and carbohydrates ( 52 ,  1 1 3 ) .  Deficiency i n  these m icronutrients and other 
sho\\ ed contri but ion to the rate and form of H I  V- I d i sease progression ( 53 ) . The B Group 
itam in  showed a ro le  in increas ing the rate of metabo l i  m (54 ), and improve immune and 
nen ou system funct ions ( 52 ) .  
B v itam ins  are a l so important for the funct ion ing of a heal thy immune system. 
V i tamin  B6  plays an essent ia l  ro le  in susta in ing and preserv ing a heal thy immune s stem by 
contribut ing to some funct ions such as cel l mu l t ip l ication and production of ant ibod ies. Some 
immune system pha es are affected by itam in  B6 deficiency i nc l ud ing  the types and amount 
of antibod ies and the number of wh ite b lood cel l s .  Supplementat ion of v i tamin  B6 may 
enhance the immune system in o lder peop le, hence reduc ing the r isk of i nfect ion ( 52 ) .  
V i tam in  B 1 2  defic iency may cause reduction i n  the  number of white b lood cel l s  
\\ h ich causes i ncreased vu l nerab i l ity to  i nfect ion.  In  one of the recent study, the  response to 
bacterial pneumococcal acc i ne has shown impairment in e lderly pat ients with 10\\ v i tam in  
B 12  leve l s  ( 5 1 ) . 
8. 1 0  Dietary S u p pl e m e n ts a nd I n fection i n  Dia betic pa t ients 
From the ev idence that support the benefit of d ietary supplements on hea l th .  it has been 
est imated by the U . S .  Centers for D isease Control and Prevention that 40% of U .S .  adu l ts, 
consume supplements regu lar ly ,  which cost about$ 1 . 3 to $ 1 . 7 b i l l  ion yearly. About ha l f of 
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the e people u e a m ixture of itam in  and m ineral upplement ( 5 8 ) .  I n  K about 25% of old 
pe p ie u nutr i t ional supplement (64) .  number of stu d ie  ha e investigated the 
assoc iati n b t"" een immune function and v i tam in  or m inera l  supp lementat ion.  ome of 
the e tudie ugge t that upplem ntat ion \\ iih mu l i i nutrients can enhance immune function 
of certa i n  group of popu lat ion \\ ho are at r isk for i nfect ions such as the e lderl} (20, 2 L 6 1 ) . 
Other hO\\ ed the oppo ite effect on immunologic response mai n l }  i n  those who u ed more 
than the recommended amount of  certa i n  d ietary supplements (62,  63 ) .  
random ized, p lacebo contro l led tria l ,  conducted in Gram pian ,  cot land invo lved 
9 1 0  part i c ipant aged 65 ,  g i \  en a dai ly  supplementat ion or p lacebo of mu lt i  i tam in  and 
m ineral for one year, and moni tored for primary i nd icators i nc l ud ing i nfect ions. se lf 
reported day of i n fect ion ,  qua l i ty of l i fe, and secondary i nd icators inc luding ant ib iotic 
prescript ion . hospital adm i ss ions, and adverse events. Th i study showed that regu lar 
upplell1entat ion of mu l t iv itam in  and m inera l s  to o lder people l i v ing  at home does not 
i nfluence se l f  reported i n fect ion re lated morb id i ty (65 ) . 
The ro le  of  some m ic ronutrients supplementat ion,  as a prophylact ic to de lay the onset 
of DM, i n  tho e with h igh r isk to develop the d i sease t i l l  not proven . However some 
v i tam in  were found to contribute to  maintain ing  lo\\ er b lood g lucose levels i n  d iabet ic 
pat ients .  For example v i tam in  E or vanad ium supplementat ions shO\ ed ev idences of 
improv i ng i n su l i n  act ion (56 ) . I t  i s  bel ieved that maintain i ng  b lood g l ucose leve l s  as c lose to 
normal as poss ib le  may p lay ro le  i n  prevention of the chron ic compl icat ions of d i sease. 
Genera l l y  it is accepted the healthy food may contribute to the contro l  of i nfect ion, 
severa l researches have repolted the rel at ion of part icu lar foods and nutrients to 
i nflammation. few stud ies have looked at the effect of d i fferent d ietary sty le  on the 
i nflammator) ind icators. In a Japanese study, 7802 subjects were involved i n  2 years study to 
exam ine the re lat ion bet\ een d ietary sty les and c ircu lat ing h igh-sens i t iv ity C - react ive 
prote i n  ( hs-C RP)  i n  Japanese people has shown that the heal thy d ietary sty le  may be re lated 
to inh ib i t ion of  i nflammation (66) .  An  I ran ian study a i med to eval uate the re lat ionsh ip  
between major d ietary patterns and the markers of systemic inflammat ion among I ran ian 
women .  The study determ i ned 3 major d ietary patterns us ing factor analys i s :  The first one 
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\\ a the heal th) d i etary pattern which i characterized by lo\\ er intakes of energy and 
holestero l and h igher i ntake of itam in B -6, magnes ium,  and fiber. The econd one wa 
the \\ e tern d ietary pattern, w h ich is characterized by h igher i ntakes of energy and 
chole tero l and lower intake of itam i n  8-6, magnes ium,  and fiber. The th i rd one w as the 
trad i t iona l  d ietary pattern which i characterized by s l i ght ly lower energ in take than tho e in 
the lo\\ e t categor) , but the ir  nutrient i ntakes were not igni ficant ly d i fferent in most cases ( P  
> 0.05 ) .  The study uggested an independent assoc iat ion between i nflammatory markers and 
major d ietary pattern (67) .  
Recent l )  Barri nger and co l l eagues ha e reported that mu l t i v i tam in  and m ineral 
upplement ign i ficant ly  reduced se lf-reported i n fect ions in 1 30 healthy people age 45 to 64 
year or o lder \\ i th most of the benefic ia l  effect seen in undernourished people with d iabetes. 
The study w as a randomized double-b l i nd,  p lacebo-contro l led tria l ,  where the treatment 
group received da i ly  tab let conta in  v i tamins  and m inera l s  im i lar to  those avai l ab le  i n  
majority of the  commerc ia l  tab lets, and the  p lacebo group received a da i ly  oral tab let conta in 
ca lc i um 1 20 mg. magnes i um 1 00 mg, and itam in  B2 3 .4 mg. Both tablets wou ld look l i ke 
and rne l l  i m i lar to the treatment one. The study showed that 73% of the p lacebo group 
reported an i n fect ious i l l ness in comparison with 43% of treatment group (p <0.00 1 ) . The 
i nfect ion-re l ated absenteei sm from work for the p lacebo was 5 7% in comparison with 2 1  % 
for the treatment group ( p  <0.00 1 ) . I t  a l so showed that amongst the i nd iv iduals  of type 2 DM 
93% of  p lacebo group repOlted i n fect ions wh i le i n  treatment group it  was on ly 1 7% (p 
<0.00 1 )  [2 1 ] . 
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9 RATIO AL FO R T H E ST U DY 
The E i the econd h ighe t wor ldwide for d iabete mel l itus  prevalence. People are at risk 
of dc\ e loping T) p 2 d iab te \\ hen the) are obese or 0 erweight .  W ith  the changes in th 
l i fe t) Ie  uch a the reduct ion in the level of ph s ical  act i ity which is affected b) the 
change in c l i mate and a gro\\ i ng dependenc) on technologies. and consumption of h igh-fat, 
and h igh energ food the i nc idence of d iabetes is i ncrea i ng rap id ly .  
I n fect ions are a major concern in d iabet ic pat ients. People \\ i th d i abetes are more 
prone to i nfect ion . e er i t) and compl ications of some i nfect ions a l so increased when they 
occur  in d i abet ic pat ients. tud ies howed that d iabet ic adu lts are at more risk for infect ion­
re lated mortal i ty .  
an) i mmune funct ion factors ma) contr ibute to this increased r isk such a reduced 
ant iox idant i tam i n  act iv i t ies involved in bacteriocidal act iv i ty. 
1u l t i v itam i n  and m i neral supplement to type 2 d iabet ic pat ients showed some impact 
in reduc i ng ome i n fect ions i nc l ud ing  respi rator infect ions ,  flu and gastro i ntest ina l  
i nfect ions i n  other part of the \\ or ld,  hO\ ever evidence i s  i ncomplete. Th is  m ight be due to 
the i n fl uence o f  the supp lement on the current nutr i t ional  defic iencies of the pat ients, wh ich 
cou ld  be re lated to poor ly contro l led d iabetes. I t  i s  a l so uggested that mu l t i vi tam in may he lp 
people who are overweight ,  have d iabetes, \ ho may have poor nutr i t ion or \ ho have 
underl) i ng d i sea es. 
To our knowledge, t here are no stud ies conducted i n  the UAE that exam ined the 
effect of d ietary supp lement on r isk of  i nfect ion i n  pat ients with type 2 d iabetes me l l i tus .  
This tudy a imed to i nvest igate the effect of ant ioxidant and B -group v i tam ins on risk of 
i n fect ions in commun i ty free- l iv i ng pat ients with type 2 d iabetes me l l i tu s .  Resu lts obta ined 
from th i s  stud) , may provide an important data for the health care profess ionals about the 
antiox idant and B-v i tam ins  n utr i t ional  status of pat ients with type 2 d iabetes, and may a l so 
he lp  to reduce morb id i ty and i mprove outcome of th i s  vu lnerab le group of pat ients by 
reduc ing the increased r isk of i n fect ion .  
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C h a p t e r  II 
1 0  M E H O DO LOG Y 
1 0. 1  H } pot h e  i 
There i� r du ed immun i ty and an increase in  ri k of i nfection i n  pat ients \\ i th t) pe 2 
d iabete . upplementary B-group itam ins \ ith ant ioxidants \v i l l  enhance itam in  status and 
antiox idant capac i t) and reduce the r isk of i nfect ions 
1 0 .2  P u rpo e o f  t h e  i nve  t igat ion 
The purpo e of the tud wa to 
1 .  Determ in  the ant iox idant and B-v i tam ins  nutr i t ional status of pat ients \ i th type 2 
d iabetes. 
tud) the effect of B -group itam ins and ant ioxidants on risk of i nfect ions in 
commun i t) free I i  i ng pat ien ts with type 2 d iabetes mel l i tus .  
1 0.3 DE S I G N  OF T HE T U DY 
random ized, double-b l i nd  p lacebo-contro l led tr ia l  
l OA Sett ing  
Al l  pat ients \ i t h  type 2 d iabetes mel l i tus v is i t i ng the  outpat ient d iabet ic services at the 
Tawam hospital for regul ar fo l low up of their d i abetes ere considered for the study. 
Ta\\ am hospital is one of the 1\ 0 main teach i ng ho p i ta ls i n  the c ity of  A I  A in  serv ing a total 
popu lat ion of 400.000. The outpat ient d iabet ic  service of Taw am hospital  is accessed by an 
average of 1 43 2  pat ients per month . The total number of pat ients seen in the c l i n ic for the 
) ear of 2009 was around 1 7 1 88 pat ients, most ly  local UAE C i t izens .  
1 0 .5  P lace the  experi m e n t a l  work was con d ucted 
Pat ients with type 2 d iabetes regu lar ly attend ing the Tawam Hospi ta l  outpatient c l i n ics were 
approached and i nv ited to take part in the study 
1 5  
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1 0.6  De cr ipt ion o f  ex per imenta l  proced u re 
Th d i n i a randomized contro l led tr ia l  of the eFFects of ant ioxidant v i tam in  (vi tam in  
and E )  and B-group \, i tam i n  ( Fo l i c  a i d ,  V i tam i n  B2 .  Vi tam in  B6 .  and  V itam in  B 1 2 )  
supplem ntat ion o n  \, i tam in  tatu . ant iox idant capac ity. and r i  k of i n Fect ion i n  pat ients \\ i th 
ty pe 2 d iabete mel l i tu . We random ized 1 00 pat ients with ty pe 2 d iabetes regu larly 
attend ing the outpat ient d i abet ic  c l i n i c  at the Tawam hospital between : 
Ant iox idant , i ta m i n  (v itam in  C and E )  and B-gro u p  ita m i n  ( Folate. B2 ,  B6, B 1 2 ) 
[ n  50 ] ;  or a place bo for 90 day [ n=50 ]  
1 0.7  t u d. protocol 
Fol lowing i nformed \\ r itten consent and thei r recru itment to the study, e l ig ib le pat ient had a 
non-fa t ing 1 0  m l  of b lood taken for measurements of antiox idants, B group v i tam ins ,  and 
re lated nutr i t ional and biochem ica l  variab les at base l i ne. Pat ients were then randomly 
as igned to receive a cap u le of ant iox idant i tam ins [ 22 1 mg) of a-tocophero l  and 1 67mg of 
\ itam in  C] and B-group  itam i ns alone [ 1 .67 mg  fo l ic ac id ,  1 .67mg v i tam in  8-2 , 20. 58  mg 
\ i tami n  8-6. 0 . 1 34 mg itam in  8 - 1 2 ] ;  or an ident ical  p lacebo dai ly  for 90 days. Pat ients 
othem ise managed accord i ng to standard practice. C l i n ica l  assessment that i nc l uded control 
of d iabetes and assoc iated r isk factors and compl icat ions \ as a l so performed at base l i ne, and 
repeated at 3 months.  Fru its and vegetable i ntake, phys ica l  act i v ity and rate of i nfections 
\\ ere a sessed at 3 and 1 2  months post-randomizat ion. 
1 0 .8  S u pplem e n ts a nd p lacebo 
The P l acebo tab let \\ as i dent ica l  to the act i e supplement v i tam in  capsu le .  0 doctor, 
invest i gator, nurse. re l at i  e of a pat ient could d i fferent iate between the act ive treatment 
capsu le  and the p l acebo capsu le  
1 7  
1 0.9 a fef) a n d  efficacy o f  the  do age 
i tam in  . E. B2 .  B6 ,  B 1 2  and  Folate : 
The l i t rature concern ing the safety of the e itam in  ha been rev iewed i n  deta i l .  
Th i  l e \  e l  of supplement ha  not been a ociated with an) adverse effect i n  human 
populat ion ( 1 34) .  Furthermore double of the e doses ha e been used in previous stud ies 
\\ i 1h no s ide efr ct be ing reported . 
T bl 5 1 t bl f '  a e . : a e o  v l ta m l l1S a n  d t h  . t f e lr  con cen ra IOn 
I ngred ient  i n  dec reas ing  weight  I n put  per Ca psu le 
o rder Ca psu le 
in mg 
I T  M I  E PO W D E R  ATURAL 22 1 .000 Vitam in E 
(CO\ itol l 2 1 0 E ) 
(d-alpha- Tocopheryl Hydrogen 
succinate) 
I T  1 C- COR B l C  C I D  1 67 .000 V itam in  C 
CAP U L E- I Z E  O- H PMC- 96.000 Capsu le  she l l  ( Hydroxypropylmethyl 
W H I TE/W H I TE ce l l u lose, hydroxypropylce l l u lose, 
propylene g lyco l  as stabi l i zer. color-
Titan ium d ioxide) 
1 IC R C R  YSTAL L I  E 79.000 As fi l l i ng agent 
C E L L U LOSE 
PYRJ DOX E 20 .580 V itam in  B6 
H YDROC H LO R I DE 
MAG E 1 UM TEARATE 7 .946 as flow and re lease agent 
R l BOFLAVr  1 .670 V itam in  B2 
FOL I C  AC I D  1 .670 fo l ic ac id  
CYA OCOBALAM I  0 . 1 34 Vitam in  B 1 2  
1 8  
Recru i tment  of pa t ient  , i th  type 2 d ia bete 
1 0. 1 0 I nc l u  ion c ri teria 
• I nd iv idua l  aged 1 8  y ear and over with t 'pe 2 d iabetes.  
1 0 . 1 1  E x c l u  ion c r iteria 
• I nd i v idual  \\ i th  ev er chron ic  c l i n i cal or p ) ch iatr ic d i sea e 
• part i c ipat ing i n  other i nter ent ion tr ia ls 
• Have an medica l  i l l ne  s or treatment "" h i ch i l i kel to i nfluence the imm une response 
and r i  k of i nfection other than d iabetes mel l i tus .  
• nab Ie to give an i n formed written con ent. 
The e. c l u  ion criter ia \\ ere de igned to e l im i nate i nd iv idua l  \ .  ho m ight have d i fficult  
compl)  ing \\  i th the i nter ent ion .  
1 0. 1 2  Con e n t  ( See ppend ix  1 )  
I n formed written consent was obtained from al l pal1 ic ipants who agreed to take part i n  the 
stud) . Local re earch eth ica l  comminee appro a l  has been granted . 
1 0. 1 3  Random izat ion  s tra tegy 
The random izat ion sequence \Va generated us ing computer generated tables, concealed i n  
con ecut ive l)  numbered preserved opaque envelopes and  kept i n  a c ler ical office.  
Outcome measures 
• utrit ional  status i n c l ud ing; Body vv e ight, Body Mass I ndex ( B M l ), and waist 
c i rcumference. 
• Measures of fru it s  and vegetables i ntake. 
• Exerc i e and ph s ica l  act i v i ty. 
• B lood pres ure, l i p id  profi le  & v itam ins  markers . 
• R isk of i n fect ion ( number of i n fect ions and inc idence of se l f- reported i n fect ion) .  
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1 0. 1 4  a m ple ize ca lcu la t ion  a n d  a na l ' e 
pre\ I O U  stud} ha  ho\ n that supplementation of d i  t with 400 mg of itam i n  increased 
p ia  ma v i tam i n  C b) 45% (37 ) .  Therefore a sample s ize of 96 diab t ic pat ients (50 treatment 
and 50 contr I ) \\ ou ld a l low the detect ion of a 30% d i fference between gr ups in total 
p lasma v i tam i n  concentrat ion \ ith 80% power and t pe 1 error probab i l i ty of � 0.05 . 
1 0. 1 5  Com plia nce w i t h  t ri a l  medicat ion 
The compl i ance of  the \ o l unteer random ized to the supplements and p lacebo \\ as a sessed 
b) : ount ing  the rema i n i ng supplements tablets at fo l low up v i s i ts and analys is  of b lood 
\ i tam in  le\ el co l lected i mmed iatel after the end of the supp lement per iod.  
1 0 . 1 6 M ea u re o f  n u tr i t io n a l  status  ( See Append ix  I I I )  
I n  l ude : Bod) \\ e ight,  Body Mass I ndex ( B M ! ), and waist c i rcumference. 
1 0. 1 7  Mea u res of fru i ts a n d  vegeta bles i n t a ke ( ee append ix I V )  
A n  abbreviated semi -quant itat i ve food frequenc quest ionnai re designed for se l f-
adm in i strat ion fol lo\\ i ng  a brief erbal d i scuss ion was used to assess subject ' s  fru it and 
vegetables i ntake. I t  pec i fies the usua l  frequency o f  consumpt ion of food items during the 
prev ious 1 2  months and asses es the average week ly  nutrient consumpt ion of each 
ind i" idual . The fu l l  vers ion of the quest ionnaire ha  been developed and val idated aga inst 7 
day weighted d ietary i ntake. I t  has a l so been compared w ith numerous other d iet sand u ed 
i n  man} other stud ies ( 1 3 5 ) .  These quest ionnai res were not val idated i n  the UAE,  but it was 
val idated i n  many other countr ies .  
1 0 . 1 8  E xerci  e q uest io n n a i re ( ee append ix  V) 
A quest ionna i re was used to assess occupat ion and le isure-re lated ph sical act i v ity. Data 
were obta ined on frequency and durat ion of dai ly or weekly phys ica l  act iv i ty sess ion for at 
least 20 m i nutes or more i n  wh ich  subjects became breath less or sweat i ng. Quest ions v ere 
a l so asked about the number of hours subjects spend i n  bed (th i s  i nc l uded t ime spent read ing, 
".:atch ing  te le i s ion or s l eep ing) .  
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1 0 . 1 9  I n fect ion d i a t")  ( ee append ix 1 )  
I n fect ion i n  tdence data were obta ined from s )  mptoms and treatment check l i st d iaries 
record d through tel phone i nter iew . U ing the infect ion inc idence d iary re ord the 
re ear h officer then a s igned a pec i fic d iagnos i s  and durat ion of i l l ness. tandard criteria 
,\-ere u ed to d i agno e common adu l t  infect iou i l lne e (upper re p i ratory tract, 100\ er 
re pi rator) tra t i nfect ion ,  i n fl uenza- l i ke i l l nesse , ore throat, s i nus i t i s, sk in infect ions, eye 
and ear i n fect ion . ga tro i nte t ina l  i n fect ions ,  and uri nary tract i nfect ions (65 ). 
1 0 .20 Blood a m ple 
Whole b lood am p Ies were drawn i nto 2 Vacutai ner tubes, conta in ing  potass ium EOTA as 
ant icoagu lant .  The samp le  vv ere thorough ly m ixed at room temperature and immed iate ly  
transferred to the laborator) (UAE Un i  ersity - F M H S, Room 3 E 1 63 ) . Both tubes were 
centri fuged immed iat I) for 1 0  m i n  at 4000 rotat ions/m i n .  P l asma and serum ,\- ere col lected 
and stored at -80°C for future determ inat ions of  v i tam in  A, C ,  B 1 2 , E ,  and  Folate. 
1 0.2 1 Reagen ts a nd I n  t r u m e n ts 
For \ i tam i n  B L,  Folate . K FTs, H bA l c, and b lood ugar analys is ,  , e used reagent ki t  from 
acce s reagent kit from BACKMA COULTER.  We anal ze a l l  these samp les on (un icel 
OXI 800 access i m m unoassay system and unicel OXC 880i synchrone access c l i n ical  
system) .  
For  v itam i ns A ,  E ,  and C ,  ana lys i s  done us ing H P LC,  and i t  was performed on a Waters 
( M i l ford. M A )  ystem grad ient l iqu id  chromatography (mode I5 1 5 ) with auto i njector (model 
7 1 7) .  
Vita m i n  A ( Ret ino l ) :  
The est imat ion was made based on the  reference:  H PLC of smal l molecules by  M J .  hearer. 
To 1 00 II I of p lasma known concentrat ion of 0 .5 1lg Im l trans-ret ino l  acetate in ethanol 1 00 III 
is ( i nternal Standard ) , as added and m ixed . Th is  was fo l lowed by the add it ion of 200 II I of 
extract ion so lvent hexane, m ixed for 30  seconds and then transferred to a shaker for 1 0  
m inutes . The upper hexane l ayer that conta ins  both ret ino l  and ret i no l  acetate was remo ed to 
another eppendorf tube and evaporated to dryness under a s l ov stream of n i trogen at 40°C . 
The res idue was reconst i tuted i n  1 00 III of  ethanol and 20 )..lJ was i njected onto a HPLC 
2 1  
) tern \\ ith co l  umn (00 406X250mm BE  K M  ) and \ i th 1 00% methan I as the 
mobi le pha e. detector et at 325 IJm carried out e t imat ion of ret ino l . 
Vita m i n  ( L-A corbic Acid ) :  
H PLC tem \" i th a fl uore cent detector carried out itam in C e t imat ion .  Deprote in i sed 
p ia  ma \\ as treated \\ i th ac tate buffer and ascorbate oxidase i n  order to ox id ize L .ascorb ic 
acid to d hydr L .a corbi a id  and further deri at i sed b OPDA to enhance fl uorescence 
and ub equent l )  in ubated before i njection to H PLC . Th i s  method by A .J peek et a l ­
Journal f chromatography , 305 ( 1 984)53 -60. to est imate the tota l ascorbic ac id takes care of 
the oxidat i ,  10 of L .a corbic acid dur ing the process of col lect ion , transportat ion etc.  A75 
�t I volume \\"a i njected onto a re er e phase coloumn (CHROMPAC K-C 1 8  1 00MM X 
4.6 1 M )  and e l uted wi th  a potass ium d i -h) d rogen phosphate/methanol mob i le phase. flo 
rate 1 m l/m inute . fl uorescent detector was used with exc i tat ion 365 lJm and em ission 4 1 8  
I)m .  
Vita m i n  E .  (a-Toco ph e ro l )  
The \ i tam i n  E e t imation were performed with B . L . Lee, S .C .Chua et a l ,  Journal o f  
chromatograph) 5 8 1 ( 1 992)  4 1 -47 .  
P i a  ma tocophero l was extracted us ing butanol-eth} I acetate mixture ( I :  I )  v/v a long 
\\ i th the i nternal tandard . tocophero l  acetate. Subsequent to proper m ix i ng. incubat ion and 
centri fugat ion.  1 0 �I of the supernatant \ as i njected onto a 3 .9 X300mm C 1 8  reverse phase 
H PLC coloumn ( WATER ) and e l uted with methanol 89 .5  %, Butano l  5% and water 5 . 5  %( 
V i\!) 1 i xer. Detect ion was carried us ing a U V  detector at 295 I)m .  
Ph i l ips latex-free b lood pressure cuffs was used to  obtai n  the  b lood pressure, and pu lse. 
Body compo it ion analyzer TA IT A model was used to obta in  the anthropometric read ings 
of the part ic i pants. 
1 0 .22 Stat istica l A n a l  sis 
Data analys is  was performed us ing  the S PSS-PC software package vers ion 1 7 .0 .  
Descr ipt i  e stat i st ics  for base l ine covariates \' ere assessed by us ing frequenc ies for 
Categorical  vari ab l es and mean for cont inuous variables i nc lud ing  the demograph ica l ,  soc io 
medica l ,  c l i n ica l ,  and med ica l  h i story and med icat ions var iab les. and to determ ine the 
d i fferences between the treatment and p lacebo groups across a l l  categorical variables Chi­
square tests \\ ere used,  and across a l l  cont inuous variab les cross tab les were used . 
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Paired ample T-Te t u ed to determ i ne igni  ficant improvement in  the b lood 
concentrat ion lev e l  of v i tam ins  at ba e l i ne, and after three months of supplements 
adm in i  trat i n. 
I ndependent ample T-T \ a used to compare the means of the v i tam i n ' s  b lood 
con entrat ions Ie e l  of the t reatment and p Jacebo ind i  iduals ,  and to compare the d i fferences 
in the number of i n fect ion at 3 month and 1 2  months of the stud) between the t reatment 
and placebo group.  I I  stat i t ica l  te t \\ ere performed at the 5% s i gn i ficance leve l .  
1 0 .23 Qua l ity a s u ra nce 
To opt im ize accuracy of  data, the co l lected data compi led for data entry and analys is ,  and the 
paper based form wer ecured and protected. Dur ing the proce s of data entry cont inuous 
check ing and compari on of the accuracy of data entry performed and double checking of 
data entr) b) two d i fferent operators \ as carried out. A random aud i t  of 20 cases of the 
entered data aga inst the paper based forms " as done twice by tv 0 d i fferent operators, and 




C h a pt e r  III 
1 1  RE U LT 
1 1 . 1 Ba e l ine  c h a racteri  t ic  
1 00 d iabet ic  pat ient \ \  ere rec ru ited to  the  tudy. 3 8  of those who received the p lacebo and 
30 of tho e \\ ho recei  ed the supplements over three month ' s  period came for 3 month 
rol lo\\ up. E:-..c l us ions \\ ere due to refu a l  for fo l low up and l ack of compl iance \\ ith study 
III d icat ions .  The general character ist ic of the part i c i pants are hO\ n in (Table 1 0 . 1 ) . 58% 
of them \\ ere females and 42% of  them were males, the mean of the part i c i pants' age was 
52 . 5  year . I n  regard to the educat ional  level statu , the study showed that the educat ional 
level or  majorit, of  th  part i c i pant was less than the h igh school level ( 79%).  and one fi fth 
of th pat ient \\ ere at graduate level or above. W ith regard to the co-morb id i t ies, most of 
the ubjects i n  01  ed in the tudy, shO\ ed two or more co morb id i t ies, with h pertension and 
h igh cholesterol being most common. 
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Table 1 0 . 1 :  Pat ie n t '  genera l cha racteri t ic . n= 1 00 
ge mean ( D) 5 1 . 5 ( 1 1 . 5 )  
F male 58 ( 5 8%) 
:::: H i gh school * 79 ( 79%) 
LeHI of educat ion  I n  ( % ) ]  
> H igh chool 1 9  ( 1 9%) 
Pa t medica l  h i  tory [ n  ( % ) ]  
Hypertension 62 (62%) 
I schem ic Heart Di sease 1 5  ( \ 5%) 
Cerebrovascu lar d isease 1 ( \ %) 
Periphera l ascu lar d i sease 3 (3%) 
Atria l  F ibri l lat ion 3 (3%) 
H igh cholestero l 74 ( 74%) 
Smoker 8 ( 8%) 
* H igh schoo l :  1 2  years of school study. 
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1 1 .2 Ba c l ine  c h a racteri  t ic of t reatment  g ro u p  co m pa red wi th  placebo group 
The part i i pant \\ ere rand m l )  a igned to  placebo ( 50) ,  or  treatment 50 ) . When comparing 
the general characteri t i c  of the two groups, a part of the waist c i rcumference in male 
pat ient . \ \  h ich i I i n  treatment group than that i n  the placebo group. the re t of the 
v ariable ho\\ ed no ign i ficant d i fferences between the t\\ O group . 
The majority of  the study popu lat ion was UAE nationa l .  Educat ional level a l so 
ho\\ ed no d i fference among the part ic ipants i n  the t\ 0 group , most of them be ing below 
the graduate leve l ;  ( 76°'0) and (85 A%) re pect ively in p lacebo and treatment groups. There 
\\ a a l  0 no stat i t i ca l  s i gn i ficant d i fference i n  the durat ion of the d iabetes between the two 
group . (Table  1 0. 2 )  
There were no s i gn i fi cant d i fference ben een the both groups i n  the type and number 
of drug the) u ed, there were a l so no s i gn i ficant d i fference between them in  the co 
morb id i t ie uch as hyperten ion and cholesterol (Table l OA)  
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T bl 1 0 2 B r a e ase me  C a ractenst lcs 0 t reatment  gro u p a n p ace 0 gro u p  h f d )  b 
P lacebo ( n-SO) T rea t ment ( n-SO)  
Va riable  N (%) N (% )  
Gender ( female)  32 (64° 0) 27  ( 54%) 
moking 2 (4% ) 6 ( 1 2 . 5%) 
AE 39 (78%) 39 ( 78%) 
at ional it) 
Others 1 1  (22%) I I  (22%) 
:SH igh school 38 ( 76%) 4 1  ( 8 5 .4%) 
Level of educat ion 
>H igh school 1 2  (24%) 7 ( 1 4%) 
<5 years 1 7  ( 3 5 .4%) 1 4  (28 .6%) 
Durat ion of  d iabetes 5 - 1 0  years 1 4  (28%) 1 0 (20%) 
> 1 0 years 1 7  (34%) 25 ( 50%) 
p:S 0.05 ign i ficant 
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p-va lue  
0..+ 1 6  
0. 1 55 
1 .000 
0.309 
0 .29 1 
The mean ag of  the treatment group i s im i lar to that of the p lacebo group ( 5 1 . 8 
y ear 5 1 .2 y ear ) resp ct i e ly .  The nutr i t ional tatus markers. revealed that. among the 
female \\ ho formed 58°'0 of the tota l sample number. stat is t ica l  I) there w as no ign i ficance 
bel\\ een the t\\ O groups. in term of the body \ e ight .  Body Ma I ndex ( 8 M  1 ). and waist 
c i rcumfl rence.(p=0.474 ). (p=63 7) .  and (p=0.665 ) re pect ive ly .  On the other hand, the male 
populat ion ho\'\ ed tati t ica l  ign i ficant d i fferences on ly  in the waist c i rcumference 
(p=0.02.t). \\ h i le bod) \\ e ight. and 8 M l  showed notable d i fferences, but it \\ u not 
tut is t ica l l )  i gn i fi canL (p=  0 .086) .  (p =0.093 )  respect ive ly .  a tat i st ica l  s ign i ficant 
d i fferen \\ ere een in other c l i n ica l  and b iochem ical  data ind icators . I nc l ud ing  kidney 
funct ion tests. HBA I C .  fa t i ng  b lood ugar (Table 1 0J ) 
The tud) ho\\ ed that. 40% of the part i c ipants \ ho received the supplements were 
rather on insu l i n  therapy a lone for d iabetes, or on combinat ion of oral hypogl )  cemic agents 
and i nsu l i n .  compared wi th  24% 0 f the p lacebo group. Stat i st ica l l y  we d idn '[ fi nd s ign i ficant 
d i fference bet\\ een the t \\ O groups (p= 0 .085) . We a l so found that 92% of those i n  pl acebo 
group receive at least one med icat ion besides the medicat ions of d iabetes, compared with 
96°'0 of the subjects o f  the treatment group (p= 0.4 1 4 ) .  The study a lso found that 68% of 
d iabet ic pat ient l ocated in the p lacebo group, suffer from hypetiension compare with 56% in 
the treatment group (p= 0 .2 1 6) .  The pre a lence of  h igh cho lestero l i n  both groups was ( 72%) 
in p lacebo compared \\ ith ( 76%) i n  treatment group.  Both groups showed that 78% of the 
part i c ipants in each group suffer at least one or more co-morb id i t i es .  (Table 1 0 .4a) 
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T bl 1 0 3 B r h a e ase me  c a ractenst ics of t rea t ment  g ro up a n d  placebo g roup 
Placebo(n-
50) T rea tment (n -50)  
Va riable Mea n  ( D )  M e a n  ( S O )  p-value 
g 5 1 .2 ( 1 1 . 8 ) 5 I . 8  ( 1 1 .3 )  0 .798 
Male 90. 1 ( 1 8 . 8 )  80 . 6  ( 1 5 . 3 )  0.086 
Bod) \\ e ight - kg Female 78 .4 ( 1 5 .9 )  82  (2 1 .2 )  0.474 
Male 3 1 .4 ( 5 .7 )  28 .5  (4 . 5 )  0 .093 
Bod) Ma s I ndex ( B M ! )  
kg/m2 .  Female 32 . 7  (6 . 1 )  3 3 . 5  ( 7 . 5 )  0.637 
Male 1 1 0.4 ( 1 2 . 8 )  1 0 1 . 5 ( 1 1 .6)  0 .024 
Wai  t c i rcumference - cm Female 1 03 . 1  ( 1 3 .2 )  1 0 \ . 5 ( 1 3 .2 )  0 .665 
ysto l ic B l ood Pres ure - m m Hg 1 33 .6 ( 1 5 .9)  1 3 7 . 5  ( 1 8 . 7  ) 0 .28 1 
Diasto l i c  B l ood Pressure - m m Hg 77 .6 ( l 0 . 5 )  80 . 6  ( 1 0 .2 ) 0. 1 58 
rea - m mollL 6 . 8( 1 1 . 5 )  6 . 1 ( 7 . 7  ) 0 .750 
Creat i n ine - mmolfL 5 8 . 7(25  ) 72 .2  (40.6) 0 . 1 93 
H B A I C  - % 8 . 1 ( 2 . 2  ) 8 .0  ( l .9 )  0 .802 
Random b lood sugar - m mo l/L 1 0 .6 (3 . 7  ) 1 1 . 2  (4 .2 ) 0 .562 
p� 0 .05 s ign i ficant 
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a bl 1 0 4 B r e . a ase me  c l a racterist ics of trea t me n t  and  placebo gro u ps 
Placebo( n-50)  T rea t me n t( n-50)  
Va ria ble N (% )  N ( % )  
I nsu l i n  1 2  (24%) 20 (40%) 
Ora l hypo 50 ( 1 00%) 47 (94%) 
gl) cemics  
Ca channe l  b locker 1 (2%) 2 (4%) 
D rug d i u ret ic  8 ( 1 6%) 6 ( 1 2 .2%) 
ACE 1 3  (26%) 1 2  (24 .5%) 
B B lockers 1 4  (28%) 1 6  ( 32 .7%) 
N itrate 0 (0%) 1 ( 2%) 
Aspir in  36 ( 72%) 40 ( 8 1 .6%) 
Others 38 ( 76%) 36 ( 73 . 5%) 
Total n u m ber of pat ients on  d rugs 46 (92%) 47 (95.9%) 
Hypertens ion 34  (68%) 28 (56%) 
I schemic heali d i sease 8( 1 6%) 7( 1 4%) 
Cerebrovascu lar d isease 0(0%) 1 (2%) 
Past 
m edical  Peripheral ascu l ar 1 (2%) 2(4%) 
hi tory d isease 
Atr ia l  fibri l lat ion 1 (2%) 2(4%) 
H igh cho lesterol 36(72%) 38( 76%) 
Others 1 2(24%) 1 4(28%) 
Total n u m ber of pat ients w i t h  past 
med ica l h istory 39 (78%) 39 (78%) 
p:S 0.05 s ign i ficant  
3 1  
p-va lue 
0.085 




0.6 1 4  
0 .3 1 0  
0 .275 
0. 772 
0. 4 1 4  
0.2 1 6  
0. 779 
0 .3 1 5  
0 .558  




t O A b :  Ba c l ine  cha racteri t ic  o f  re  ponder  a n d  non-re ponder  of the  tudy populat ion 
I'" 
Respondents  ( n-68 ) N o n - respondents ( n-32 ) 
Va ria ble N ( % )  N ( % )  p-value 
Age mean ( SO)  50 ( l 0 ) 54 ( 1 4 ) 0 . 1 94 
Gender (male) 28  (4 1 %) 1 3 (4 1 %) 0 .958 
Smok ing 4 (6% ) 4 ( 1 2%) 0 .485 
E 53  ( 78%) 32  (78%) 
ational it -
Others 1 5  (22%) 0 0 .292 
:SH i gh school 55 ( 82%) 24 (77%) 
Le\ el of educat ion > H igh chool  1 2 ( 1 8%) 7 (22%) 0 .387 
Bod) weight - kg 
mean (SO) Ma le  83  ( 1 8 ) 79 ( 1 8 ) 0.296 
B 1 1  kgfm2 Ma le  32 (6 .6)  3 1  ( 5 . 5 )  0 .387 
mean (SO)  
Waist 
c i rcumference -cm 
mean (SO)  Ma le  1 04 ( 1 2 ) 1 02 ( 1 3 .6 )  0 .567 
Urea - mmollL mean ( S O) 7 . 5 ( 1 1 . 3 )  4 .2 ( 1 .3 ) 0 . 1 1 1  
Creat i n ine - mmollL mean ( S O )  7 J (46 ) 64 ( 1 4 ) 0 .388 
H B  I C - 0 0 mean ( SD)  8 . 3  (2 .2  ) 7 . 8  ( 1 . 8 ) 0 .286 
Random b lood sugar - m mo llL 
mean ( 0) 1 0 .7  ( 3 . 8  ) 1 1 . 5  (4 ) 0.457 
0 .338 
Total number of patients on drugs 67 (98%) 32( 1 00%) 
Total number of patients wi th  past 
med ical  hi tory 52 (76%) 26 (8 1 %) 1 .000 
p:S 0.05 s ign i fi cant 
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rable l OAc:  Re ponder ba e l ine  c h a racteri t ic of treatment  a nd placebo gro u p  
Placebo( n -38)  T reatment ( n-30) 
Va ri a ble N ( %l N ( % )  p-va lue  
V\ge mean ( 0) 50 ( 1  I ) 50  (9)  0.9 1 5  
pend r (male)  1 5  ( 39%) 1 3  (43%) 0 .748 
Smoking 1 ( 3% ) 3 ( \ %) 0. 1 7.f 
Nat i nal i t) UAE 28( 73%) 25 ( 83%) 
I 
Other 1 0 (22%) 5(  1 7%) 0.229 
, �H igh chool  30  ( 79%) 25 ( 83%) 
Le\ el 0 f educat ion > H igh school 8 (2 1 %) 4 ( 1 3%) 0.443 
�od) \\ e ight - kg 
jnean ( 0) ale 83 ( 1 6 .9)  84 (20)  0. 769 
� M l  kg m2 
mean (SO)  Ma le  32 (6)  32  ( 7 . 5 )  0 .953 
�\Va i  t 
i rcumference -cm 
r1ean (SO)  Ma le  l OS ( 1 3 ) 1 03 ( 1 1 ) 0 .656 
8 . 7( 1 S ) 6 .9 (9 .6 ) 0.682 
rea - mmol/L mean ( S D) 
�reat in ine - mmo llL  mean (SD)  5 7(29 ) 77  (50)  0 .2S9 
iHBA I C  - % mean ( D)  8 . 5  (2 . 5 ) 8 ( 1 .9 )  0'-+S9 
Random b lood sugar - mmo l/L  
mean (SO)  1 0 . 2  ( 3 . 8 ) 1 1 . 1  (4 ) 0 .4 1 8  
0 .282 
ITotal number of patients on drugs 3 8  ( 1 00%) 29(97%) 
Irotal number of patients with past 
med ical  h istory 29 (75%) 26 (80%) 1 .000 
p� 0.05 ign i ficant 
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rra ble l OAd:  on-re po nder ba e l ine  c h a racteri  t ic  o f  t rea t m e n t  and placebo gro u p  
Placebo ( n - 1 2 )  T reatmen t( n-20)  
Variable N (%) N (%) p-value 
gc mean ( 0) 54 ( 1 4 ) 54 ( 1 4 ) 0 .9 1 2  
nder (male)  3 (25%) 1 0 ( 50%) 0. 1 63 
mok ing 1 ( 8% ) 3 ( 1 5%) 0 .58 1 
E 1 1 (92%) 1 4  ( 70%) 
at ional it) 
Others 1 ( 8%) 6(30%) 0 .335 
�High school  8 (66%) 1 6  ( 8 5%) 
Le. e l  of educat ion > H igh school 4 ( 34%) 3 ( 1 5%) 0 .255 
Bod} \ \  e ight - kg 
mean ( 0) Male 82 (2 1 ) 77 . 5  ( 1 6) 0.472 
B M I  kg ml 
mean (SO)  Ma le  32 .6  ( 5 . 6 )  30  ( 5 .4 )  0.2 1 0  
Waist 
c i rcumference -cm 
mean (SO)  Ma le  1 08 ( 1 5 ) 99 ( 1 2 ) 0.074 
4( 1 . 5 )  4 . 3 ( \ . 3 ) 0.65 8 
Urea - mmollL mean ( S D) 
Creat i n ine - mmol/L mean ( S D)  60.6( 1 9 . 7  ) 65 .6( 1 l .3 ) 0 .454 
H B  I C - %  mean ( S D )  7 . 7 ( 1 . 5 ) 7 .8  ( 1 .9 )  0 . .  909 
Random b lood sugar - m mol lL  
mean (SD)  L 1 . 7 ( 3 . 7  ) 1 l . 3  (4 .8 ) 0 .853 
0 448 
Total number of patients on drugs 1 2  ( 1 00%) 1 9(95%) 
Total number of patients " i th past 
med ica l  h i story 1 0  (83%) 1 6  ( 80%) 0 .883 
p� 0 .05 s i gn ificant 
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The female i nd iv idua l  compared i n  table ( 1 0 .3 &4a) showed no stat ist ica l  s ign i ficant 
d i fference between the treatment and p lacebo groups two group . I n  Table  ( l OAb) we looked at the 
male ind iv iduals and compared the base l i ne characterist ics in term of the of gender. national i t  , 
le\ 'e l  of educat ion,  tota l medicat ions,  med ica l  d iseases, smoking, body weight, BMl ,  KFTs, HbA I c ,  
and b lood ugar of  the responders and non-responder part i c ipants. The study showed that there 
v" ere no tati ti al s ign i ficant d i fferences between these t\ 0 groups .  
Table ( \ O .4c) ho\\ that ,  among the re ponder subjects the mentioned base l i ne characterist ics of 
treatment and p lacebo groups there were no stat i st ical s igni ficant d i fferences. There were a lso no 
stat ist ical ign i ficant d i fferences between the treatment and p lacebo groups among the non­
responders tab le  ( l OAd) .  
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] 1 .3 E ffect of u pp lement  o n  v i ta m i n  tatu  : 
I n  both group , erum blood Ie el of v i tam ins wa checked basel ine and 3 m nth fol lo'v\ ing 
omplet ion of the upplement. The b lood Ie e l s  of the five vitam ins ;  B 1 2 , Folate, , C , and 
E of the pIa ebo group ubject howed no tat i ti al i gn i ficant d i fference betw een the 
ba e l i ne and the '" month [o l l o\\- up,(p= 0 .229),  (0 .736), (O .OS I ), (0 .066), and (0 .696) 
r p t i \ e l ) (Tab l  1 0 . 5 ) . W h i le the three month foi l  0\ up of erum itam i n '  levels in  the 
treatment group have hO\\ 11 that; V i tam in  E, B 1 2 , and Folate have s ign i ficant ly increased 
( P=0 .003 ), ( P=0.03 ) .  ( P=0 .002 ) ,  ( P=O.OOO) respect ively .  W h i le in V itam i n  A, the leve l 
dropped from 0 .9  to O . S  ( P=0. 7 1 6),  and Vitam i n  C dropped from 30 . 1 to I S . S  ( P=0.005)  as 
ho\\ n i n  (Table 1 0 .6 ) .  
\.Vhen comparing  the ba  e l i ne  v i tam ins level i n  both group we found that, V itam in 
B 1 2 , Fol ate, and V itam i n  C had sho\\ n no stat ist ica l  i gn i ficant d i fferences ( p=O. ! OS) ,  
( p=O.SO� ), and ( p=0.23 ! )  respect ive ly .  The ba e l i ne of v i tam ins  C. A, E ,  and Folate \\ ere 
h igher i n  the treatment group than that in p lacebo group, and it v as on ly  V itam in  B 1 2  the 
ba e l i ne wa 10\\ er i n  treatment than the p lacebo. V itam in A, and V i tamin E had shown 
tati t ica l  ign i fi cant d i fference ( p=O.OOO), and ( p=0.002) respect ive ly .  The serum blood 
lev e l  of v itam i n ' s  i n  both groups after 3 months of supplementat ion showed that, except in 
\ i tam in C the leve l s  in the treatment group were h igher than that in the p lacebo group. The 
stud) ho\\ ed that. the base l i ne re u l ts with the one done after three months ;  the placebo 
group bow ed that v itam i n  B 1 2  and v i tam in  C level s  dropped, wh i le v i tam i n  A, E, and Folate 
a lmost ho\\ ed no change. 
There was s ign i ficant improvement i n  fo late, B 1 2 , and E in treatment group, 
compared " ith  p lacebo group.  However no d i fference was seen i n  V itam in  A .  despite the 
fact the V itam i n  C dec l i ned in both groups (Tabl e  1 0 . 7a, b, c) .  
The d i fferences in the numbers of the samples at 3 and 1 2  months wa due to the fact 
that ,  some pat ients agreed to have the food and exerc i se d iary assessment, as we l l  as the 
i nfect ion d iary but refused to give b lood. 
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Table  1 0 . 8  hoy the d i fference i n  v i tam in concentrat ions bet\v een base l ine and 3 
month i n  b th group . The tudy showed that, the d i fference i n  v itam in  A .  E .  and fo late 
c ncentrat ion between ba e l ine and 3 months in the p lacebo group compared \\ ith the 
treatment group \\ ere tat i t ica l l )  s ign i ficant ( p=0.002, p= 0.005,  p= 0 .00 1 )  respecti e l ) . 
Wh i le in \ i tamin  B 1 2  and itam i n  there were d i fferences but d idn ' t  reach to stat ist ical 
s igni  fi  ance ( p= 0 .62 1 ,  p=O. 1 65 )  respecti e l  . 
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Table 1 0 . 5 :  V i ta m i n  blood level i n  placebo b a  e l ine  a nd 3 m o n t h  fo l lo\\ u p  � 
Placebo ( n= 3 8 )  
Base l ine  3 months  
Var iab le P-va lue 
Mean ( D) Mean (SD)  
itam i n  B 1 2-pg/m l  237 .6  ( l 00 . 8 )  224  (97 .6)  0 .229 
Folate - ng/ml  1 8 .3  (8 .9 )  1 8 .6  ( 8 .4 )  0 . 736 
V itam in  C - )lmollL 24 .9  ( 1 7 . 5 )  1 9 . 1 ( 1 1 . 8 )  0.08 1 
V i tam i n  A - Ilmol lL 0 . 55  (0 .290) 0 .64 (0 .390) 0.066 
V itam in  E- IlmollL 7 .4 (4 . 5 )  7 . 7  ( 4 . 5 )  0 .690 
p:::: 0.05 s ign i ficant 
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Ta ble 1 0 . 6 :  V i ta m i n  blood Ie, e l  i n  t reatment- ba e l ine  a n d  3 m o n t h  fo l low up 
T reatment  ( n-30) 
Va riable  P-va lue  
Ba e l ine 3 m o n t h  
Mean ( D) Mean ( D) 
V itam in  B 1 2-pg/m l  1 8 1 .4(92.6) 252 . 5 ( 1 87 .9 )  0.002 
Folate - ng/ml  1 9 .2(7 .9)  32 . 8 ( 1 1 . 8 )  0 .000 
V itam in  C - �lmol/L 3 3 . 1 (20 .8)  1 8 . 8 ( 1 2 . 5 )  0.005 
V itam in  A - �mol/L 0 .8(0 . 33 )  0 . 82(0 .29)  0 .7 1 6  
V itam i n  E- �mollL  8 . 7(3 .2 )  1 1 .2(4 . 5 )  0 .030 
p:S 0.05 s ign i fi cant 
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T bl 1 0  a e . / a :  V ' t  . I I ' d ' b f b ' d I a m m  eve l S m 13 e IC su  �Jects on t rea t me n t  a n  placebo. 
P lacebo T rea t m e n t  
( n= 38 ) ( n= 30 ) p-\'a lue 
Variable Ba e l i n e  3 month  Ba  e l ine  3 months  Ba e l ine  3 month  
Mean ( D)  Mean ( S D) Mean ( D) Mean ( D) 
itam i n  B 1 2- 252 . 5 ( 1 87. 
p� m l  237 .6( 1 00 . 8 )  22-+(97 .6)  \ 8 1 .4(92.6) 9) 0. 1 08 0 .432 
Folate - n g/ml  1 8 . 3 ( 8 . 9 )  1 8 .6 (8 .4)  1 9 .2 (7 .9)  32 .8 (  1 1 . 8 )  0 . 804 0.000 
Vitam in  C -
/-llTI 0 ilL 24 .9( 1 7 . 5 )  1 9 . 1 ( 1 1 . 8 )  33 . 1  (20 .8 )  1 8 .8 ( 1 2 . 5 )  0 .23 1 0.9 1 9  
V i tamin  A -
�lmollL 0 .5 5(0 .290)  0 .64(0 .390) 0 .8(0 . 33 )  0 .82(0 .29)  0 .000 0 .038 
V itam in  E-
/-lmollL 7 .4(4 . 5 )  7 .7 (4 .5 )  8 .7 (3 .2 )  1 1 .2 (4 . 5 )  0.002 0.002 
p:'S 0 .05 s ign ificant 
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Ta ble I O .7 b: Vita m i n  level i n  d ia bet ic u bject on t rea t m e n t  a n d  placebo. 
Group tat i  t ic  
group N Mean Std. Dev iat ion td. Error Mean 
IVitB 1 2  P l acebo 50 237 .60 1 00 .86 1 1 4 . 1 23 
Treatment 50 1 8 1 .42 92.6 1 5 .008 
VitB 1 2 ( F )  P lacebo 38  224.08 97 .620 1 5 .836 
Treatment 30 252 . 50  1 8 7 . 89 1 34 .304 
Folate P l acebo 50 1 8 . 300000 8 . 782895 1 .24 1 4376 
Treatment 50 1 9 .220000 7 .928 1 5 72 1 . 1 494950 
Folate( F )  P lacebo 3 8  1 8 .6263 1 6  8 . 54580 1 6  1 . 3700899 
Treatment 30 32 .769000 1 1 . 83725 1 6  2 . 1 6 1 1 766 
IV I T  P l acebo 50 . 5 59200 .295 1 92 1  .043 1 607 
Treatment 50 .868400 . 3325 746 .0583469 
IVlT  (F )  P l acebo 38  .644474 .3932999 .06380 1 7  
Treatment 30 .828333 .29797 1 1  .05440 1 8  
IV I T  C P l acebo 50 24 .873 800 1 7 .650880 1 2 . 3 547900 
Treatment 50 33 . 326400 20. 86443 70 2 .9506770 
V lT C(F)  P lacebo 3 8  1 9 .065263 1 1 . 8490 1 65 1 . 922 1 643 
Treatment 30 1 8 .759333  1 2 . 5 7 5 7394 2 .2960054 
V l T  E P l acebo 50 7 .403000 4 .4546408 .60 1 697 1 
Treatment 50  8 . 732200 3 . 2322694 . 58439 1 1  
V I T  E( F )  P lacebo 3 8  7 . 706579 4 . 5650827 .7405542 
Treatment 30 1 1 . 2 1 8000 4 . 54 1 1 433 .8290955 
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Table l O .7c :  Vi ta m i n  Ie e l'  i n  d ia bet ic u bject on t rea t m e n t  a n d  placebo. 
Le ene's Test for t-test for Equal ity of Means 
Equal i t) of ariances 1 95% Con fidence Int er al of the Difference 
F I g. t df ig. (2-tai led) 
itB 1 2  Equal \ ariance assumed .0 1 9  . 892 1 .624 98 . 1 08 
qual  \ ariances not assumed 1 .624 97 .640 . 1 08 
i tB I 2( F )  Equal \ aIiances a umed .950 . 333  - . 806 66 .423 
qual variances not assumed - .752 4 1 .2 1 0  .456 
Folate Equal  v ariance assumed .060 .806 - .248 98 . 804 
Equal ariances not assumed - .248 97 .425 . 804 
Folate( F) Equa l  \'ariances assumed 8.440 .005 -5 .746 66 .000 
Equal  variances not assumed -5 .5'27 50. 590 .000 
IT A Equal variances assumed 2 . 1 89 . 1 42 -5 .087 98 .000 
Equal variances not assumed -5 .087 90.268 .000 
v rT A( F) Equal  variances assumed 2 .580 . 1 1 3  -2. 1 23 66 .038 
Equal  variances not assumed -2. 1 93 65 .909 .032 
lT C Equal  variances as umed 3 . 1 77 .078 - 1 . 206 98 .23 1 
Equal  ariances not assumed - 1 .206 93 .404 .23 1 
IT q F) Equal variances assumed . 1 28 .72 1 . 1 03 66 .9 1 8  
Equal  variances not assumed . 1 02 60.574 .9 1 9  
IT E Equal variances assumed .0 1 0  .92 1 - 3 . 2 54 98 .002 
Equal vaIiances not assumed - 3 . 2 54 97 .9 1 7  .002 
V IT E( F) Equal  variances assumed . 1 69 .682 -3 . 1 57 66 .002 
Equal variances not assumed -3 . 1 59 62 .53  - .002 
p:S 0.05 s ign i ficant 
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Ta ble 1 . 8 :  the  d i fference i n  v i ta m i n  concentrat ion  between ba e l ine  a nd 3 month In 
placebo co m pa red w i t h  the  tr  a t ment  g ro u p  
P lacebo T rea t m ent  
( n= 38 ) ( n= 30 ) 
Va riable Ba c l ine  3 months Ba c l i ne 3 months  p- a lue  * 
Mean ( D) Mean ( 0) Mean ( S O) Mean ( D) 
i tam in  B 1 2-pg/m l 237 .6( 1 00.8 )  224(97.6) 1 8 1 .4(92.6) 252 . 5 ( 1 87 .9)  0 .62 1 
Folate - ng/m l 1 8 . 3 ( 8 .9 )  1 8 .6( 8 .4)  1 9 .2 (7 .9)  32 .8 (  1 1 . 8 )  0 .00 1 
V i tam i n  C - ) ..ullo11L 24 .9( 1 7 . 5 )  1 9 . 1 ( 1 1 . 8 )  3 3 . 1 (20 .8 ) 1 8 .8 ( 1 2 . 5 )  0. 1 65 
V i tam in  A - )..lmollL 0 . 55 (0 .290) 0.64(0.390) 0 .8(0 .3 3 )  0 . 82(0 .29)  0.002 
V itam in  E- )..lmollL 7 .4(4 . 5 )  7 . 7(4 . 5 )  8 . 7 (3 .2 )  1 1 .2(4 . 5 )  0.005 
* Test of between -Subject effects. 
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F igure ( 1 0 . 1 a. b, c ,  d, e )  a l  0 show the comparison between the b lood \ i tam in 
concentrat ion at  ba e l i ne and 3 month i n  pl acebo group compared \ i th the treatment group. 
Fig u l'e 1 0 . l a : Vi ta m i n  B 1 2  level i n  d ia betic s u bject at base l ine  a n d  3-mo n t h  i n  
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P lacebo T reatment 
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o Placebo basel ine 
o Placebo 3 months 





Fig u re l O. l b : fo late level i n  d i a betic u bject at ba e l ine  a n d  3-month  i n  treatment  
group com pa red w it h  p lacebo group 
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o Placebo base l i ne 
o P lacebo 3 m onths 
o Treatm ent base l i ne  
o Treatm ent 3 months 
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0 , 8  
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Fig u re I O . l c : Vi ta m i n  A level i n  d iabetic u bjects at ba e l ine  and  3-month  in  
t r'eat ment  gro u p  co m pa red w i th  placebo gro u p  
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1 0 Placebo basel ine 
o P lacebo 3 months 
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o Treatment 
basel i ne 
3 months 
igu rc l O . l d :  V i ta m i n C level i n  d ia betic u bject a t  ba e l ine  a n d  3-month  in  
t rea t ment  g ro u p  co m pa red with placebo g ro u p  
Vita m i n  C 
35
1 30 o P lacebo base l i ne  25 D P lacebo 3 m onths 20 1 
1 5 o Treatm ent base l i ne  1 0  5 D Treatm ent 3 m onths 
0 
bas e l i n e  3 m onth s  bas e l i ne 3 m onths 
P lacebo Treatm ent 
47  
Figu re l O . I e : V i ta m i n  E levels i n  d ia betic u bject a t  ba e l ine  a n d  3-month  in  
t rea t ment  gro u p  com pa red with placebo g roup 
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1 1 .4 E ffect  of u pp lement  o n  i n fect ions :  
Table 1 0 .9 ho\\ s the frequencie of i n fect ion i n  treatment group compared '\l i th p lacebo 
group. The re u l ts howed that at three months fo l l ow up, the total number of part ic ipants 
\\ ho repol1ed i n fect ion in the treatment group \ a 9 part i c i pants out of 34 part ic ipant 
completed the tab let , and re p nded to the i nfect ion d iary que t ionnaire C:27° 0).  Wh i le in the 
placebo group out of 42 part i c i pant completed the tab lets, 1 5  subjects had reported 
infect i n ( "6%).  A l though the number of subjects experi enced i nfect ions in the placebo 
grou p \\ as more than those i n  the treatment grou p, the d i fference between the two grou ps ,v as 
not tat i st i ca l l )  ign i ficant ( p=0.623 ) .  
Tab le  1 0 . 1 0  sho\\ s the  number of i nfect i ons e peri enced by  the  part ic i pants i ll the 
p lacebo group, compared \\ ith those in the treatment group at 1 2  months fol lows up. The 
re u l t  revealed that, the number of part i c i  pants who reported i nfections in the treatment 
group \\ ere 25 part i c i pants (67 . 5%), wh i le in the p lacebo group the tota l number of 
part i c i pants \\ ho reported i n fect ions was 27 part i c ipants (56 .3%).  
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Ta ble 1 0 . 9 :  F req uencie  of i n fection over 3 month  i n  d i a bet ic u bject of 
t t t d I b rca men  a n  p ace 0 g roups 
Placebo T reatment  
Ty pe of i n fection ( n="2 )  ( n=34) p-va lue  
old  2 4 . 7%) 0 
F l u  
2 (4 .7%) 0 
ore throats 1 (2 .4%) 1 (2 .9%) 
Bronch i t i s  0 1 (2 . 9%) 
r i nary tract i n fect ion 0 1 (2 .9%) 
Gastro enter i t i s  (d iarrhea and 
\ om it i ng) 1 ( 2 .4%) 0 
Ear i nfect ion 1 (2 .4%) 1 (2 . 9%) 
Other 8( 1 9%) 5( 1 4 . 7%) 
Tota l n u m be r  of i n fection 1 5(36%)  9(26% ) 0.623 
p:::: 0.05 s igmficant 
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Ta ble 1 0 . 1 0 :  F req uencie of i n fection over 1 2  month  in d iabetic s u bject of trea tment  
d I b a n  pi ace 0 gro ups 




Bronch i t i  
r inary tract i n fect ion 
Gastro enter i t i s  (d iarrhea and 
omi t ing) 
Ear i n fect ion 
Other 
Tota l n u m be r  of i n fect ions 
p::S 0.05 s ign ificant 
Placebo T reatment  
( n=48) ( n=37) p-value 
3 (6.25%) 4 ( l 0 . 8%) 
4 ( 8 .3%) 5 ( 1 3 .5%) 
4 (8 .3%) 3 ( 8 . 1 %) 
2 (4.2%) 1 (2 . 7%) 
3 (6 .25%) 2 ( 5 .4%) 
0 I (2 . 7%) 
2 (4 .2%) 1 (2 .7%) 
9 ( 1 8 . 8%) 8 (2 1 . 7%) 
2 7  (56.3%)  25  (67. 5 % )  0.488 
5 1  
1 1 .5  Food i n t a ke 
Tab le 1 0 . 1 1 h \\ the food and d ietar i ntake of the ind i  idua ls  i nvolved i n  the stud) . \\ h ich 
\'v a e a l uated throughout the re earch :  at three month and 1 2  months.  i ng a tandard 
que t ionnaire, part i c i pants of  both groups were requested to answer quest ions about the 
number of the � d items th ) consume per week. The response rate i n  the placebo group 
\\ as h igher than the treatment group (86%) compared with (64%) respect i ely. The study 
a l so i nd icat d a 011 of match ing among the part i c i pants in the ame group as we l l  as between 
both groups.  0 s ign i fi cant d i fference stat ist ica l l y  seen between the two group . except in the 
t i nned or dr ied fru i t  ( p=O.OOO) .  
1 1 .6 E xerc i  e a nd phy  ical  act iv ity 
Tab le 1 0 . 1 2 re ea l s  the 3 months phy ica l  act iv ity of the part i c ipants in both groups. the 
tud) found that. the majori t  of  the d iabet ic pat ient who were i nvo l ed i n  th is stud) 
reported 10\\ rate of ph s ica l  act iv i ty; 5 1 % of the subjects of  the p lacebo group said that they 
hm e not very act i ve nature of  occupat ion,  compared with 37 . 5% in  the treatment group, and 
-1-2° 0 of the p lacebo reported moderate ly occupat ion compared with 56% in the treatment 
group. The d i fference between the t\VO groups were found not stat i st ica l l y  s ign i ficant 
( p=0.29 1 ) . l n  term of the le i sure time 3 7% of the p lacebo group described not be ing very 
t ime.  compared \\" i th 40% i n  the treatment group, and 56% of  p lacebo stated moderate 
act iv i ty compared with 5 9% i n  the treatment group, with no stat ist ica l  s ign i ficance 
( p=0.5 1 7) .  The majority of part i c i pants reported low rate of  physica l  act iv ity. 'v\ hich lead to 
breath less and sweat i ng, wi th  no d i fference between the t\  0 groups. 
Tabl e  1 0 . 1 3 shows the 1 2  months fol low up of both groups i n  term of the physical 
act iv i t ies. The stud sho\ ed a lmost s im i lar resu l ts of  the 3 months survey, physical act iv i t ies 
at occupat ion were 10\\ i n  p lacebo and treatment groups ( 5 8%) and (68%) respect ively 
( p=OA I 8 ), le i sure t i me found to be not very act ive i n  75% of the p lacebo, compared with 
650'0 of  the t reatment ( p=0 .3 72) .  No stat is t ica l l y  s ign i ficant d i fference were seen i n  the 
number of  hours per week part i c ipants spend doing housework ( p=0 . 1 26),  48% of placebo 
ubjects reported phys ica l  act i v ity, which lead to breath less and S\ eat ing less than once per 
week, compared with 52% of the treatment subjects ( p=0.29 1 ) . 
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Ta ble 1 0  1 1  F d d '  . d '  b f b ' 00 J a ry In Ja  e JC su IJects on t reatment  a n d placebo 
P lacebo T reatment  
Va riable n=43 n=32 
n u III ber/"" eek number/week 
mean (SD) mean ( S O) 
3 m o n t h  1 2 m o n t h  3 m o n t h  1 2 months  
pp le  and pears 3 .2 (2 . 8 )  5 .5 (2 )  2 .8  ( 2 . 3 )  5 . 5  ( 1 . 8 )  
Orange and  bananas 4 (2 .6 )  5 .4 ( 1 .9 )  3 .8  (2 .4 )  5 . 3  ( 1 . 6)  
T inned or dr ied fru i t ,  1 . 8 (2 .4) 4 .2 (2 .4)  4 (2 .6)  5 .2 (2)  
fru it i n  ) rup or j u ice 
Fruit  ( fresh or from a 3 . 1 ( 2 .6)  3 .9 (2 . 8 )  3 (2 .6 )  3 .5 ( 2 . 5 )  
carton) 
Green vegetabl es, sa lad,  5 .6 (2)  6 (0 .9)  5 .4 (2 )  5 (2 )  
cabbage. spinach 
Potatoes. mashed, boi led, 1 .9 ( 1 .9 )  3 . 9  (2 .4) 1 .6 ( 1 . 8 )  3 .6 (2 .6)  
baked. ch i ps 
Vegetables i n  soup, 2 .6 (2 . 3 )  5 (2 )  3 .2 (2 .3 )  5 ( 1 . 8 )  
stews. ready meals etc 
Other vegetables .  peas. 4 . 1 (2 .6 )  5 ( 1 .4 )  4 .6 (2 )  5 .4 (0 .9)  
carrots, on ions ,  tomatoes 
etc 
p:S 0.05 s ign i fi cant 
5 3  
P-va lue P-value 
3 1 2  
months  month 
0.500 0.900 
0.600 0.900 
0 .000 0.090 
0 .800 0.600 
0.700 0.080 
0 .500 0. 700 
0. 300 0.900 
0.400 0 .500 
T bl 1 0  1 2  E a I e xerclse d '  . d '  b . b ' t t d I b 3 la ry an la et lc  su .,ects on t rea m e n ts a n  Race 0-
Va riable Placebo T reatment  
n=43 n=32 
umber (%) umber (%) 
I i  \\ ph) s ica l l )  a t i ve i not el") act i  e 22 ( 5 1 %) 1 2( 37 .5%) 
) our occupation 
moderate ly  act i ve 1 8  (42%) 1 8(56%) 
ery Treatment 2 (4 .6%) 0 
not work ing 1 (2 . 3%) 2(6%) 
Ho\\ phys ica l l y  act i \  e is not very act ive 1 6  ( 37%) 1 3(40%) 
y our lei ure t ime  
moderate ly  act i e 24 ( 5 5 . 8%) 1 9( 59%) 
very act ive 2 (4 .6%) 0 
1 10\\ many hours per \veek Mean 7 9 
do you pend do ing 
hou e\\ ork 
SO ( 5 . 1 ) ( 1 0 .6) 
Ho\\ often are you < 1 /week 26 (60%) 24( 75%) 
ph) ica l l )  act ive for at 
1 -2/week 8 ( 1 8 .6%) 7(22%) 
least 20 m inute . \ here 
you become out of  3 -4/week 4 (9 . 3 )  0 
breath less and s\ eat i ng  
5-6/week 1 (2 . 3%) 0 
7-8/week 1 (2 .3%) 0 
>8/week 0 0 
HO\\ many hours per day < 1 hours 5 ( 1 1 .6%) 3 (9%) 
do you usual l y  spend i n  
1 -2 hours 7 ( 1 6%) 5 ( 1 6%) 
bed(th i s  i n c l udes t imes 
spent read i ng. \yatch i ng 3 -4 hours 2(4 .6%) 0 
telev is ion.  s leepi ng) 
5-6 hours 9(2 1 %) 8(25%) 
7-8 hours 1 3(30%) 1 3(40%) 
>8 hours 5( 1 1 .6%) 2(6%) 
p:S 0.05 s ign ificant 
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h mont IS 
p-ya lue 
0.29 1 




T bl 1 0 1 3  E a c .xerCJse . d '  b J a ry 1 11 Ja  etic s u biects on  supplements a nd placebo- 1 2  mont hs 
place bo T reatment  
Va riable  n=3 1 n=3 1 P-value 
umber (%) umber (%) 
HO\\ phy ica l l act i e l  not ery acti e 1 8( 5 8%) 2 1  (68%) 
y our occupat ion 
moderatel act ive 6( 1 9%) 6( 1 9%) 
very act ive 0 
0.4 1 6  
1 ( 3%) 
not work ing 7(23%) 3 ( 1 0%) 
Ho\\ ph. ica l l )  act ive is not ery act ive 24( 75%) 20(65%) 
your le i  ure t ime  moderate ly act i e 7(23%) 1 0(32%) 0 . 372 
very active 0 1 (3%) 
Ho\\ man) hours per Mean 1 5 .6 1 2  
\\ eek do you spend do ing ( S O) (7 .9 )  ( 7 . 1 ) 0 . 1 26 
house\\ ork 
HO\\ often are you < l /\\ eek 1 5(48%) 1 6(52%) 
phys ical l )  act i ve for at 1 -2/week 7(23%) 5( 1 6%) 
lea t 20 m i nutes, \', here 3 -4/week 1 ( 3%) 5 ( 1 6%) 0 .29 1 
) ou become out of  breath 5-6/week 1 (3%) 2(6%) 
and s\\eat 7-8/week 0 0 
>8/week 7(23%) 3 (  1 0%) 
Ho\\ many hours per day < 1 hours 0 0 
do ) ou usual ly  spend i n  1 -2 hours 0 0 
bed(th i s  i nc l udes t imes 
3-4 hours 1 ( 3%) 1 ( 3%) 0.034 
spent read ing, watch i ng  
5 -6 hours 3 ( 1 0%) 8(26%) 
tele is ion,  s leep ing) 
7 -8 hours 9(29%) 1 6( 52%) 
>8 hours 1 8( 5 8%) 6( 1 9%) 
p:S 0.05 s ign ificant 
5 5  
DISCUSSION 
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Ch a pt e r  IV 
1 2  D iscu s io n :  
The purpo e o f  th i  tudy \Va to assess the effect of 3 months ant ioxidants and B-group 
\ i tam in upp lement on rate of common i n fections in type 2 d iabet ic pat ients in the 
ommun it) . Th recru ited part i c ipants were random ly selected and d iv ided into two groups; 
one group took the treatment v i tamins  and the other took an identical p lacebo. Pat ients and 
invest igators were a l l  b l ind  to the treatment a l locat ion . A l l  part i c ipants had the same type of 
a se ment, i nvest igat ions ,  educat ion and method of i ntervie\- throughout the study. 
At the end of the study \ e found that there were no s ign i ficant d i fferences between 
the p lacebo and treatment group in the general characteri st ics and measurements such as the 
age. le\ e l  of educat ion ,  B M !  and other base l i ne characterist ics .  The fi nd ings of the research 
i nd icated s ign i ficant i mpro ement i n  serum level of V itam in  E, B 1 2 . and folate in the 
treatment group after three months of i tam in ' s  consumpt ion .  The level of Vitam ins A and C 
dropped i n  both the supplements and placebo group. Th i s  ma be due to i ncreased oxid itaive 
damage resu l t i ng  i n  decrease ant ioxidant v i tam ins status 
The study a l so showed that the number of i nfect ions reported by the treatment group 
after three months of  supplements \ as less than those reported by the placebo group (9 vs.  
1 5 ) respect i  e ly: howe er t h i s  d i fference was not stat ist i ca l l y  s ign i ficant. The d i fference in 
the number of  i n fect ion became less after 1 2  months of fo l low up (27 vs .  2 5 )  respect ive ly .  
A l though the d i fference i n  the number of  reported i nfect ion might be assoc iated with the 
i tam in  supp lementat ion ,  the lack of  stat i st ica l  s ign i ficance cou ld be re lated to the low dose 
of the itam ins  used or the short period of supplementat ion,  or the effect of v i tamins  weaned 
duri ng  the 1 2  months fol l o\ up .  
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12. 1 Obe it) : 
e a l so found a h igh rate of obe ity and overweight amongst the d iabetic ubjecls in  01 ed 
i n  the tud) . Prev iou stud ies i n  E on OM ind icated h igh prevalence of obe ity among 
the d iabeti pat ient , and th a oc iat ion of d iabete \\ ith i ncreas ing wai st-hip rat io ( 73 ) . 
The E 0 0 tud) (The Emi rates at ional D iabetes tudy & creen ing � r Coronary 
rter) Di ea e R i  k Factor ) which was performed b the UAE M in i st!) of Health i n  
co l laborat ion \\ ith the World Health Organ izat ion bet\ een the year 1 998-2000 on  6.609 
ind iv idual  above the age of 2 1  years showed that 74% of the random people stud ied were 
either ,em e ight or obese ( 72 ) .  I n  our research it ha been noticed that the rate of obes i ty 
among the part i c i pants i n  our ample \\ as h igh .  32% of subjects were ovem eight ( 8 M !  
bet\\ een 25  kg/m2 and 3 0  kg/m2), and 58% o f  them were obese ( B  M I  greater than 
30 kg m2) .  We a l so found that the majority of the subjects invo lved in the stud) were 
centra I I )  obese, \\ h i cb  was determ ined by the abso lute wai st c i rcumference 
(> I 02 centimeters in men and >88 centi meters in women) (69) .  The average waist 
c i rcumference in male  subjects \ a 1 06 centimeters, and in female subjects was 1 02 
cent imeters. umerous  stud ies v,,'ere conducted to eval uate the re lat ionsh i p  between type 2 
d iabetes, and Central obe it)', and ind icated central obes ity as a pred i spos i ng factor for 
insu l  i n  res i stance (70 ,  7 1 ) . 
A l though obes i ty  as a r isk factor for several morb id cond i t ions  i s  " e l l  accepted , its 
contr ibut ion to i n fect ion has not been suffic ient ly stud ied. Many stud ies suggested that 
i n fect ions of se eral body systems are more frequent i n  obese people than those of normal 
\\ e ight (93 ) .  
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1 2 .2 Food a n d  exerci  e a e ment  
c ioe onomi  de  e lopment in the  A E  i n  the la  t three decades has affected a l l  aspects of  
the  l i fe inc lud ing the  hea l th  and d i  ea  es, the  l i fe ty le  of  the popu lat ion \-\ h ich \-vas 
i nfluen ed b) i m pro ement in education and the i ntroduct ion of the techno logies. Thi has 
b en a oc iat d \\ i th decreased I ve l s  of physical act iv i t) and i nc reasing consumpt ion of 
h igh calor ic food I ad i ng to obe it) and l i nked to h igh rates of type 2 OM in the countr) 
(9 1 ) . Better ph) s ica l  acti it) level is as ociated \ ith considerable decrease in r isk of type 2 
d iabete , i nc lud ing  physi a l  act i v it  of  moderate i ntens ity and durat ion (92) .  
The Food p) ram id .  generated by the U Department of Agricu l ture ( USDA),  
reported th importance of Fru i ts and vegetables as r ich source of nutr ients .  and good sources 
oh itam in  . i tam in  C .  and  folate. Fru i ts and vegetables are h igh i n  fiber and  lovv i n  fat .  
The Food Pyramid  recommends 3 to 5 serv ings of  vegetables each da ( 1 30) .  Fru i t are an 
ea ) way to meet the body' s need for v itam i n  l i ke and C.  Vegetables are a l so recogn ized 
as r ich ource of i tam in s, m inera ls ,  ce l l u l ose, and fiber. Green leafy vegetables ha e h igh 
level of v itam in s  , C , E, K and fol ic ac id .  Carrots are agood source of  V itam in  A. Potatoes 
are a good source of V itam i n  C .  V i tamins are found in abundance in fru i ts  and vegetables. 
part i cu lar l) the ra\\ vegetab le  and fresh fru its ( 1 3 1 ) . 
The food i ntake, certa i n l y  fru i ts and vegetables of  the part ic ipants \\ as taken i n  
con iderat ion;  i t  ''''as recorded a t  three months v i s i t  a s  wel l  a s  at 1 2  months i n  order to  adjust 
for the ir  e ffect  011 v i tam i n  Ie  e l s .  We found that there were no s ign i ficant d i fferences 
bet\\ een the two groups in fru i ts and vegetables i ntake at 3 and ] 2 months. We a l so used an 
exerc i e d iar) to mon itor ph) s ica l  act iv ity duri ng the study period. We found that, the 
majorit) of the palt i c i pants in both groups were not very act ive, and few were moderately 
act ive. For i n stance in term off the act i v i ty at work. \ e found that ,  at 3 months 5 1  % of the 
p lacebo group subjects were poorly active and 42% were moderate ly  act ive, compared with 
38% poorly act i ve and 56% moderate l y  act ive in the treatment group.  The exerc ise 
assessment of the same fie ld repeated after 1 2  months of the study, showed that 58% of the 
p lacebo group subjects were poorly act ive and 1 9% were moderately act i ve, compared with 
68% poor ly act i ve and 1 9% moderately act ive in the treatment group. 
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1 2 .3 D M  i n  U E 
The pre alence of Diabete Mel l i tus i n  AE i a major concern. recent urvey conducted 
betv .. een 1 999 and 2000 by Ma l i k  and o l l eague reported prevalence d iabetes more than 
:wo o of the people in E, th i  percentage reaches 25% among the AE national ( 73 ) . One 
in four nat iona ls  i d iabet ic  ha made UAE the econd-h ighest nation with d iabetes in 
the \" or ld .  AE  spent 436 m i l l ion ( 1 .6 b i l l ion d i rham) on diabetes-related treatments in  
2007. ;tan) res arches con firmed the h igh prevalence of OM in the UAE, and the re lated 
compl icat ions among subjects with d iagnosed and und iagnosed OM ( 74 ), which ra i ses the 
importance of needed efforts to mon i tor, e a l uate, and increase the commun i ty awareness on 
th D in order to get earl) d iagnosi which \ i J l l ead to effect ive management of the 
d i  ea e. and he l p  in the prevent ion of long-term compl icat ions .  
12A E ffect  of  DM o n  i m m u n ity and risk of i n fection 
Pat ients \v i th d iabetes me l l i tus  are con idered to be more prone to i n fect ions than those 
\" ithout OM.  The cour e of the i n fect ions is a l so more l i ke l y  to be comp l i cated among th is  
group of  pat ient ( 7 5 ) .  I t  i s  been suggested that defect in immun i ty m ight be one of the 
po ib le reason of th i s  i nc reased inc idence of i n fect ions. A prospect ive study of 1 0 1  293 
adu l t  inpatients reported that the prevalence of bacteraemia in the d iabet ic pat ients i s  more 
than i n  non-d iabet i cs ;  for 1 000 adm issions 2/3 of the bacterem ias were found i n  d iabet ic 
pat ients compared to 1 13 i n  non-d iabet i c  pat ients . (p  < 0 .00 I )  ( 76) .  
Diabetes mel l i tus  may a l so contri bute to surgical  \ ound i n fect ion .  In pat ients who had total 
h i p  rep lacement surgeries.  the wound i n fect ion rate wa I I % of 42 d iabet ic  pat ients, 
compared \\ i th 2% of 1 , 1 80 non-d iabet ics pat ients of  s im i lar age (8 1 ) . On the other hand. 
some stud ies suggested no d i fference in the surgical wound i n fect ion .  For example the 
at ional Academy of c i ences- at ional Research Counc i l  Cooperat ive tud reported that 
the surgical wound i n fect ion i n  non d iabet ic subjects ( 7 . 1 %) compared with d i abet ic  subjects 
( 7 .2%) in 3 54 subjects (79) .  In c lean orthopedic surgeries a study conducted comparing the 
203 d iabet ic and 3 ,4 1 4  non-d i abet ic  pat ients matched on age, se , and length of surgery 
found that no d i fference i n  the i n fect ion rates between the two groups(3 .4% versus 
3 .6%) [80) .  
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evera l  tudies \\ ere conducted to evaluate the effect of  d ietary supplementat ion on 
the i n fect ion rate, man of  these stud ies focu ed on the ro le  of  m i nera l s  and v i tam in 
upplementat ion i n  pre ent ion of the i n fect ions. ha anne and co l leagues i n  the ir  double 
b l ind random ized tud made an effolt to evaluate the impact of mu l t i  i tam in supplement on 
infect i n pre ent ion in h a l th) e lderly subjects. A l though they found no d i fference in rate of 
i nfect ion bet\\ een the tw o groups ,  they reported that, after 4 months of the v i tam in 
uppl  m ntat ion ,  the palt i c i pant ' s  v i tam in  b lood Ie e l s  of  v i tam ins  E, BL B2,  B6 and fo lates 
w ere igni Gcant l y  h igher i n  treatment group than i n  p lacebo group ( p  < 0.00 I ) . Their  study 
al 0 reported that b lood a corbic ac id concentrat ion after 4 months of the study wa h igher 
in treatment than in p lacebo group ( p<0.05 ) .  Vi tam in  A remained s im i lar in the two groups 
(68) .  Hovy ever the i r  tud) \\ a not long enough to eval uate the long term i nfect ions, but i t  
\\ a im i l ar to our tud)  in term of  length of  period of i tam i n  supplementat ion .  Our study 
sho\\ ed some i m i lar find ings, after three months of vitam i n  supplementat ions,  the b lood 
concentrat ion of V itam in  E, B 1 2, and Folate have s ign i ficant ly increased . W h i le in V itam in  
A. the  level dropped from 0 .9  to 0 .8 ,  and V itam in  C dropped from 30 . 1 to  1 8 . 8 .  
A l 1-month doub le  b l ind randomized study, ai med to  eva luate the  effect of i tam ins 
and trace e lements on i n c idence of  i n fect ion-related i l l ness on i ndependentl l i v i ng, healthy 
elder ly  ind i\  idua ls, reported that the mean number of  days with an i n fection-related i l l ness i n  
the p lacebo group \\as s ign ificant ly more than i n  the treatment group(48 days vs .23 days) 
(60) .  Another study reported that, a good qual ity balanced d iet, a long with appropr iate 
nutrient supplements. showed impro ed immune responses and reduced rate of common 
respi ratory i l lnesses ( 1 32 ) ,  and improved many immunological  aspects (6 1 ) .  Many other 
studies suggested an effect of d i etary supplements on the immun ity and reduce the risk of 
i n fect ion (20. 2 1 . 6 1 ) . V itam in  C may p l ay a ro le  as ant i  oxidant funct ions in inspir ing the 
immune system aga inst damage from the free rad icals re leased dur ing the i n flammation 
process (43 ) .  I t  may hel ps in ra i s ing i nterferon level of  the body, and decreases the severity 
and length  of d iseases (44) .  V i tamin  E in one study showed lower rate of i n fectious d iseases. 
compared wi tb  those who rece ived the p lacebo, and decrease upper resp i ratory tract 
i n fect ions ,  most l y  common co lds, with no effect on lower resp i ratory tract i n fect ions or 
seasonal  ( 50 ) .  V itam in  B6  with Fo l i c  Acid p lays a ro le  in regu lat i ng the leve l s  of 
homocyste ine, wh ich showed an assoc iat ion with immun ity i n  the e lderly ( 54, 1 33 ) .  
6 1  
Barr inger and co l league i n  their random ized double-bl i nd,  p lacebo-contro l led tr ia l  have 
reported that mu l t i  i tam i n  and m ineral upplements( Mu l t iv itam ins conta i ns ;  V i tamin  A, B­
car tene, B I 4, B3 ,  B6, B 1 2 , , o ,E .  K, B ioten, Pantothen ic ac id ,  and Fo l i c  ac id and mi nera l 
\\ h i ch i nc l ude mangan e, copper, I ron, Z inc ,  I od i ne, elen ium.  and Chrom ium). 
s igni  ficant l )  reduced e l  f-reported i n fect ions in 1 30 healthy people age 45 to 64 years or 
o lder \\ ith most of  the benefic ia l  effect seen i n  undernouri hed people \\ ith d iabete . The 
tud) al 0 ho\\ ed that 73% of the p lacebo group reported an infect ious i l l ness in comparison 
\\ ith 430 0 of treatment group (p <0.00 I ) . The i n fection-re lated absenteeism from work for the 
placebo \\ a 5 7% in com parison with 2 1  % for the treatment group (p <0.00 I ) . The study 
ho\\ ed that amongst the subjects w ith type 2 OM 93% of p lacebo group reported infections 
\\ h i le in treatment group  it  w as 1 7% (p <0.00 I ) . A l though the base l i ne characteri st ics of the 
sample popu lat ion i nvo lved in Barr inger study were shO\ ing that . the treatment group was 
more ph) ica l l y  act ive and better nourished than the p lacebo group but there were s im i l ar 
othen\ i e, with respect to base l i ne covariates. The majority of the sample were female, and 
bet\\ een the ages of 45 and 64 ears . About 1 0% of subjects had not fi ni shed h igh schoo l .  
T\\ o th i rd of the samp le  \\ ere overweight or obese, and about 30% had type 2 d iabetes 
mel l itu  ( 2 1 ) . 
Tak ing our find ings and that of Barr inger et a i ,  we bel ieve there is evidence, that 
certa in  v i tam ins  supplementat ion ma) ha e a ro le to p lay in impro ing immun ity and 
prevent ing i n fect ion in d iabet ic  pat ients. A l though th is  evidence is not strong, there is 
certa i n l ):  a need for l arger stud ies to confirm these findings before they can be adopted by 
heal th professional  l ook ing  after d iabet ic pat ients .  
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1 2 .5 t rength , weakne e a n d  reco mmendation fo r fut u re re ea rch 
I n  our stud ' we found that the three month of v itam in  supplementat ion played a ro le 
in increas i ng mo t of itam in '  b lood level i n  the i nd i  idual of the treatment group 
mpared \\ ith the p lacebo group.  Th i d i fference in the v i tam in ' s  b lood Ie e l  between the 
t\\ O groups as oc iated \\ i th lo\\ er but stat ist ica l ly  not a s ign i fi cant d i fference in the i n  idence 
of infect ion in th supplement group compared with the placebo group.  Ho\\ e er th is  
d i  fference a lmo t d i  appeared at  1 2  months most I ike l  due to  the fact that supplement were 
topped at 3 month of  the study period. It is poss ib le  that i f  the v i tam ins dose was h igher, 
upplement period was l onger or the sample s ize was larger we might have seen bigger 
d i fference in the rate of i n fect ions bet\', een the supplement and the p lacebo group. 
l though comp l i ance \\ i th the tr ia l  med icat ions  was ery good and supplements i ncreased 
\ i tam in Ie el s ign i ficant ly  in the b lood nearly one quarter of our subjects sample refused to 
ha\ e b lood taken for itam i n  analys i s  at 3 months. Howver further analysis of base l i ne 
characterist ics d i d  not re eal s ign ifi cant d i fferences between those \ ho agreed to have 
outcome data col lected from them and those who d id not. 
In our study, we re l ied on the pat ient sel f  report i ng technique in record ing inc idence 
of i nfect ions .  Th i s  m i ght ha e i ntroduced a marg in  of error in thei r report ing of the true 
i nfect ion rate. I t  is poss ib l e  that, \ e cou ld have obtained a more accurate and re l iable 
informat ion on i n fect ions rate i f  another method of col lect ing i nformat ion \ as used such as 
revie\\ i ng pat ient s hospi ta l  records track c l in ics  records where the part i c ipants had v is i ted 
and obta ined treatment, or s imp ly  hav ing pat ients to cal l for every s i ngle epi sode of infect ion 
he/she experienced, or even conduct ing more regu lar v is i ts  or ca l l s  to check the cond it ion of 
the pat ient. but th i s  \\ ou ld  requ i re more resources and i s  very t ime-consum ing. 
Th i s  study has many strengths i nc lud ing the select ion of subjects \ hich was random. 
the p lacebo contro l l ed des ign and the double-b l i nd nature of i ntervent ion treatment and 
assessment. The study was conducted prospect ive ly, where the subjects of both groups were 
fol lo\ ed over a 1 2  months,  and most of the re levant measurable con found ing factors were 
taken i n  cons iderat ion such as the food i ntake and level of act iv ity of the part i c ipants .  The 
double-b l ind  nature meant that neither part ic ipants nor the assessors were aware of which
 
treatment group subjects belong to unt i l the end of the study. The p lacebo tre1tment 
\Vas 
identical to the treatment .  No subjects or researcher cou ld recogn ize the d i ffere
nce between 
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the placebo and the treatment v i tam ins. i n  add i t ion al location equence \\ a general d by 
meone d i fferent from tho e i n  o lved i n  the recrui tment and fol l O\\ up of the stud) 
part i i pant . 
The tud) a l so conducted over one year, th i s  i to l im i t  the effect of  the external 
factors on the tud) , and to have more comprehen ive data inc lud ing the easonal ariat ion, 
and th pat i nt " ere i nt e r  ie\\ ed th ree t imes by a s ingle observer. us ing a tandard checkl ist .  
Future tudie need to focus on the mechan isms of the d ietary supplement on the 
imlllun i ty  y tem and rate of i n fect ions;  it is strongly recommended to increase the sample 
ize of  the part i c i pant 0 that the effect ohvi thdrawal or not complet ing the tudy can be 
exc l uded . A larger c l i n ica l  tr ia l  i s  requ i red to find out whether these resu l ts can be appl ied 
not on l)  in d iabet ic  persons but a l so in any subject \\ ith a h igh rate of potent ia l  i nfect ions. 
itam in concentrat ion can a l so be increased to cover the dai l y  requ i rements, this pro\ ide 
more data about the essent ia l  dose of v i tam in needed . Extended s im i lar study for more than 
three months can also be a l uable .  
The food frequency q uest ionna ires though i t  was not va l idated in the UAE, but it was 
val idated i n  many other countries. Future study shou ld  consider the cu l ture of the country 
\\ hen design ing  or us ing  s i m i lar quest ionnaires. 
The methodo logy of sel f report i ng infect ions can be more advance through regu lar. 
and frequent i nter i ews \\ i th the part ic i pants, th i s  is to reduce re i ing on part i c ipant ' s  
memory, and to  avo id  m i ss ing  of any i n fections. Track ing the patient ' s  record for a l l  the 
i l lnesses and variation in patient ' s  condit ion dur ing the study, is recommended to col lect 
deta i led i n format ion about the nature of i l l ness. re u Its of the b lood i nvest igat ions. and any 
other essent ia l  data can he lp  in evaluat i ng and fol lowing the part i c ipants medical health 




C h a p t e r  V 
1 3  Co n c l u  i o n  
The tudy i ntended t o  e a l uate the effect o f  d ietary supplement o n  r isk o f  i nfection i n  
communi ty b a  e d  pat ient \\ i th t) pe 2 d iabete me l l i tus .  We found that, d ietary. supplements 
of the 1I ed mu l t iv i tamins ,  impro ed the concentrat ion of the b lood i tam in  level of the 
treatment group, over the 3 month of supplementat ion ign i fi cant ly compared \\ ith the 
p lacebo group.  The tud) a l so howed that, the number of se l f  reported i nfect ions in type 2 
d iabet ic pat ients of  the treatment group was Ie s than that i n  the p lacebo group, ho\\ ever the 
d i fference \\ a not tat i st ica l l y  s ign i ficant .  A larger c l i n ical  tr ia l  is des i rable to find out 
\\ hether the re u l t  can be rep l icated not on ly in d iabet ic  persons but a l so in any other 
group \\ ho are more prone to i n fect ion,  and certa in ly  those who have nutr i t ional concerns. 
I f \  itam ins supp lements are found to reduce the rate of i n fect ions i n  d iabet ics and other 
im i lar group of pat ients. wider i mplementat ion o f th i  strategy cou ld  have s ign i ficant health 
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